<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD011281.pub2" GROUP_ID="ENDOC" ID="809014021715554517" MERGED_FROM="" MODIFIED="2016-01-20 10:26:05 +0000" MODIFIED_BY="Gudrun Paletta" REVIEW_NO="T140217" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="2.0">
<COVER_SHEET MODIFIED="2016-01-20 10:26:05 +0000" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2014-08-06 18:26:50 +0200" MODIFIED_BY="Bernd Richter">Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis</TITLE>
<CONTACT MODIFIED="2016-01-20 10:26:05 +0000" MODIFIED_BY="Gudrun Paletta"><PERSON ID="z1312061231141312115076313704410" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlos</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Andrade-Castellanos</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Specialist in Internal Medicine</POSITION><EMAIL_1>caandrade@hcg.gob.mx</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"</ORGANISATION><ADDRESS_1>Salvador Quevedo y Zubieta No. 750</ADDRESS_1><CITY>Guadalajara</CITY><ZIP>44340</ZIP><REGION>Jalisco</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+52 33 361 893 26</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-01-20 10:26:05 +0000" MODIFIED_BY="Gudrun Paletta"><PERSON ID="z1312061231141312115076313704410" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlos</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Andrade-Castellanos</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Specialist in Internal Medicine</POSITION><EMAIL_1>caandrade@hcg.gob.mx</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"</ORGANISATION><ADDRESS_1>Salvador Quevedo y Zubieta No. 750</ADDRESS_1><CITY>Guadalajara</CITY><ZIP>44340</ZIP><REGION>Jalisco</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+52 33 361 893 26</PHONE_1></ADDRESS></PERSON><PERSON ID="z1310101556018579415993652055074" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Luis Enrique</FIRST_NAME><LAST_NAME>Colunga-Lozano</LAST_NAME><POSITION>Medical Resident</POSITION><EMAIL_1>dr.colunga.lozano@gmail.com</EMAIL_1><EMAIL_2>fire_hawk2002@hotmail.com</EMAIL_2><MOBILE_PHONE>+52 (044) 33 15 18 66 39</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Critical Care Medicine</DEPARTMENT><ORGANISATION>Hospital Civil de Guadalajara "Fray Antonio Alcalde"</ORGANISATION><ADDRESS_1>Calle Coronel Calderón #777</ADDRESS_1><CITY>Guadalajara</CITY><ZIP>44320</ZIP><REGION>Guadalajara</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+52 33 36383409</PHONE_1></ADDRESS></PERSON><PERSON ID="z1310101602154827271983648865722" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Netzahualpilli</FIRST_NAME><LAST_NAME>Delgado-Figueroa</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>netscience89@gmail.com</EMAIL_1><URL>http://sociedadmbe.org</URL><MOBILE_PHONE>+52 33 10701730</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Hospital Civil de Guadalajara Dr. Juan I. Menchaca</ORGANISATION><ADDRESS_1>Salvador Quevedo y Zubieta No. 750</ADDRESS_1><CITY>Guadalajara</CITY><ZIP>44340</ZIP><REGION>Jalisco</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+52 33 38109134</PHONE_1></ADDRESS></PERSON><PERSON ID="z1401201343430676420836308991502" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Daniel</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Gonzalez-Padilla</LAST_NAME><POSITION>Resident</POSITION><EMAIL_1>daniel.mx@gmail.com</EMAIL_1><MOBILE_PHONE>+34 656565183</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Urology</DEPARTMENT><ORGANISATION>Hospital Universitario 12 de Octubre</ORGANISATION><ADDRESS_1>Avenida de Córdoba, s/n</ADDRESS_1><CITY>Madrid</CITY><ZIP>28041</ZIP><REGION>Madrid</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>656565183</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-01-18 16:23:23 +0100" MODIFIED_BY="Gudrun Paletta">
<UP_TO_DATE>
<DATE DAY="27" MONTH="10" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="10" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="27" MONTH="10" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="9" YEAR="2014"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2016"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2016"/>
</DATES>
<WHATS_NEW/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2014-10-07 17:25:44 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-10-07 17:25:44 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-10-07 17:25:44 +0200" MODIFIED_BY="[Empty name]">
<NAME>Department of Emergency Medicine, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"</NAME>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<DESCRIPTION>
<P>Moral support</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-01-20 10:41:21 +0100" MODIFIED_BY="Gudrun Paletta">
<SUMMARY MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2014-09-10 16:16:29 +0200" MODIFIED_BY="Gudrun Paletta">Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis</TITLE>
<SUMMARY_BODY MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Review question</B>
</P>
<P>What are the effects of subcutaneous rapid-acting insulin analogues compared with standard intravenous infusion of regular insulin for the treatment of diabetic ketoacidosis?</P>
<P>
<B>Background</B>
</P>
<P>Rapid-acting insulin analogues (artificial insulin such as insulin lispro, insulin aspart, or insulin glulisine) act more quickly than regular human insulin. In people with a specific type of life-threatening diabetic coma due to uncontrolled diabetes, called diabetic ketoacidosis, prompt administration of intravenous regular insulin is standard therapy. The rapid-acting insulin analogues, if injected subcutaneously, act faster than subcutaneously administered regular insulin. The need for a continuous intravenous infusion, an intervention that usually requires admission to an intensive care unit, can thereby be avoided. This means that subcutaneously given insulin analogues for diabetic ketoacidosis might be applied in the emergency department and a general medicine ward.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We found five randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) with a total of 201 participants. Most trials did not report on type of diabetes. Younger diabetic participants and children were underrepresented in our included trials (one trial only). Participants in four trials received treatment with insulin lispro, and one trial with 45 participants investigated insulin aspart. The average follow-up as measured by mean hospital stay ranged between two and seven days. The study authors termed the diabetic ketoacidosis being treated with insulin analogues or regular insulin as mild or moderate. This evidence is up to date as of October 2015.</P>
<P>
<B>Key results</B>
</P>
<P>Our results are most relevant for adults with mild or moderate diabetic ketoacidosis due to undertreatment of diabetes. No deaths occurred. Time to resolution of diabetic ketoacidosis from the start of therapy did not differ substantially between the two insulin treatment schemes (approximately 11 hours). Hypoglycaemic (low blood sugar) episodes were comparable: 118 per 1000 participants for intravenous insulin compared with 70 per 1000 participants for subcutaneous insulin lispro (no statistically significant difference). The mean length of hospital stay also showed no marked differences. No trial reported on side effects other than hypoglycaemic episodes or investigated patient satisfaction. No serious events associated with diabetic ketoacidosis were seen during insulin lispro treatment.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Our results were limited by mostly low- to very low-quality evidence, mainly because the number of included trials and participants was low. Further research is very likely to have an important impact on our findings.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<ABS_BACKGROUND MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of uncontrolled diabetes that mainly occurs in individuals with autoimmune type 1 diabetes, but it is not uncommon in some people with type 2 diabetes. The treatment of DKA is traditionally accomplished by the administration of intravenous infusion of regular insulin that is initiated in the emergency department and continued in an intensive care unit or a high-dependency unit environment. It is unclear whether people with DKA should be treated with other treatment modalities such as subcutaneous rapid-acting insulin analogues.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>To assess the effects of subcutaneous rapid-acting insulin analogues for the treatment of diabetic ketoacidosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We identified eligible trials by searching MEDLINE, PubMed, EMBASE, LILACS, CINAHL, and the Cochrane Library. We searched the trials registers WHO ICTRP Search Portal and ClinicalTrials.gov. The date of last search for all databases was 27 October 2015. We also examined reference lists of included randomised controlled trials (RCTs) and systematic reviews, and contacted trial authors.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-11-04 07:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials if they were RCTs comparing subcutaneous rapid-acting insulin analogues versus standard intravenous infusion in participants with DKA of any age or sex with type 1 or type 2 diabetes, and in pregnant women.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Two review authors independently extracted data, assessed studies for risk of bias, and evaluated overall study quality utilising the GRADE instrument. We assessed the statistical heterogeneity of included studies by visually inspecting forest plots and quantifying the diversity using the I² statistic. We synthesised data using random-effects model meta-analysis or descriptive analysis, as appropriate.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Five trials randomised 201 participants (110 participants to subcutaneous rapid-acting insulin analogues and 91 to intravenous regular insulin). The criteria for DKA were consistent with the American Diabetes Association criteria for mild or moderate DKA. The underlying cause of DKA was mostly poor compliance with diabetes therapy. Most trials did not report on type of diabetes. Younger diabetic participants and children were underrepresented in our included trials (one trial only). Four trials evaluated the effects of the rapid-acting insulin analogue lispro, and one the effects of the rapid-acting insulin analogue aspart. The mean follow-up period as measured by mean hospital stay ranged between two and seven days. Overall, risk of bias of the evaluated trials was unclear in many domains and high for performance bias for the outcome measure time to resolution of DKA.</P>
<P>No deaths were reported in the included trials (186 participants; 3 trials; moderate- (insulin lispro) to low-quality evidence (insulin aspart)). There was very low-quality evidence to evaluate the effects of subcutaneous insulin lispro versus intravenous regular insulin on the time to resolution of DKA: mean difference (MD) 0.2 h (95% CI -1.7 to 2.1); P = 0.81; 90 participants; 2 trials. In one trial involving children with DKA, the time to reach a glucose level of 250 mg/dL was similar between insulin lispro and intravenous regular insulin. There was very low-quality evidence to evaluate the effects of subcutaneous insulin aspart versus intravenous regular insulin on the time to resolution of DKA: MD -1 h (95% CI -3.2 to 1.2); P = 0.36; 30 participants; 1 trial. There was low-quality evidence to evaluate the effects of subcutaneous rapid-acting insulin analogues versus intravenous regular insulin on hypoglycaemic episodes: 6 of 80 insulin lispro-treated participants compared with 9 of 76 regular insulin-treated participants reported hypoglycaemic events; risk ratio (RR) 0.59 (95% CI 0.23 to 1.52); P = 0.28; 156 participants; 4 trials. For insulin aspart compared with regular insulin, RR for hypoglycaemic episodes was 1.00 (95% CI 0.07 to 14.55); P = 1.0; 30 participants; 1 trial; low-quality evidence. Socioeconomic effects as measured by length of mean hospital stay for insulin lispro compared with regular insulin showed a MD of -0.4 days (95% CI -1 to 0.2); P = 0.22; 90 participants; 2 trials; low-quality evidence and for insulin aspart compared with regular insulin 1.1 days (95% CI -3.3 to 1.1); P = 0.32; low-quality evidence. Data on morbidity were limited, but no specific events were reported for the comparison of insulin lispro with regular insulin. No trial reported on adverse events other than hypoglycaemic episodes, and no trial investigated patient satisfaction.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Our review, which provided mainly data on adults, suggests on the basis of mostly low- to very low-quality evidence that there are neither advantages nor disadvantages when comparing the effects of subcutaneous rapid-acting insulin analogues versus intravenous regular insulin for treating mild or moderate DKA.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-01-20 10:41:21 +0100" MODIFIED_BY="Gudrun Paletta">
<BACKGROUND MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<CONDITION MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. A consequence of this is chronic hyperglycaemia (that is elevated levels of plasma glucose) with disturbances of carbohydrate, fat, and protein metabolism. Long-term complications of diabetes mellitus include retinopathy, nephropathy, and neuropathy. The risk of cardiovascular disease is increased. Individuals with diabetes may be admitted to the hospital as a result of diabetic emergencies such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS). DKA is an acute, major, life-threatening complication of diabetes that occurs mainly in individuals with autoimmune type 1 diabetes, but it is not uncommon in some people with type 2 diabetes (<LINK REF="REF-Kitabchi-2009" TYPE="REFERENCE">Kitabchi 2009</LINK>). DKA and HHS represent the most extreme consequences of uncontrolled diabetes mellitus.</P>
<P>In the USA, the incidence rate for DKA ranges from 4.6 to 8 episodes per 1000 people with diabetes of all ages, and 13.4 episodes per 1000 people with diabetes who are younger than 30 years old (<LINK REF="REF-Faich-1983" TYPE="REFERENCE">Faich 1983</LINK>; <LINK REF="REF-Johnson-1980" TYPE="REFERENCE">Johnson 1980</LINK>). The incidence rate in the USA is comparable to the rates in Europe, with estimates of 13.6 per 1000 people with type 1 diabetes in the UK (<LINK REF="REF-Dave-2004" TYPE="REFERENCE">Dave 2004</LINK>). The mortality rate of DKA currently ranges from 0% to 19%, a rate that has shown a little decline in recent years (<LINK REF="REF-Basu-1993" TYPE="REFERENCE">Basu 1993</LINK>; <LINK REF="REF-Warner-1998" TYPE="REFERENCE">Warner 1998</LINK>). Mortality rates increase substantially with age and in the presence of concomitant life-threatening illnesses such as co-existent kidney disease and infections (<LINK REF="REF-Malone-1992" TYPE="REFERENCE">Malone 1992</LINK>). Hyperglycaemic crises are also economically burdensome, as DKA is responsible for more than 500,000 hospital days per year at an estimated annual direct medical expense and indirect cost of USD 2.4 billion (<LINK REF="REF-Kim-2007" TYPE="REFERENCE">Kim 2007</LINK>).</P>
<P>The basic mechanism for the development of DKA is a reduction in the effective insulin concentration and increased counter-regulatory (catabolic or stress) hormones like glucagon, catecholamine, cortisol, and growth hormone. The hyperglycaemia of DKA results from increased hepatic glucose production (gluconeogenesis and glycogenolysis) and impaired peripheral glucose utilisation. Ketone bodies result from a marked increase in the free fatty acid release from adipocytes, with a resulting shift toward ketone body synthesis in the liver. This hormonal imbalance leads to the biochemical triad of DKA: hyperglycaemia, ketonaemia, and acidaemia (<LINK REF="REF-Kitabchi-2001" TYPE="REFERENCE">Kitabchi 2001</LINK>). People with DKA are invariably volume depleted because insulin deficiency in DKA leads to hyperglycaemic osmotic diuresis and progressive volume depletion. Glycosuria is also accompanied by large urinary losses of potassium and phosphorus. The above processes can have several consequences, including tissue hypoxia, hyperviscosity, arrhythmia, and decreased blood flow to target organs like the brain.</P>
<P>Successful treatment of DKA requires correction of hyperglycaemia, skillful fluid and electrolyte adjustments, identification of comorbid precipitating events, and above all frequent and close monitoring of the patient (<LINK REF="REF-Kitabchi-2009" TYPE="REFERENCE">Kitabchi 2009</LINK>). The treatment of diabetic ketoacidosis is traditionally accomplished by the administration of intravenous infusion of regular insulin, which is initiated in the emergency department and continued in an intensive care unit (ICU) or a high-dependency unit environment, as endorsed by the American Diabetes Association and the Joint British Diabetes Societies guideline for the management of DKA (<LINK REF="REF-Kitabchi-2009" TYPE="REFERENCE">Kitabchi 2009</LINK>; <LINK REF="REF-Savage-2011" TYPE="REFERENCE">Savage 2011</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The first priority in the treatment of DKA is to restore intravascular volume to normalise tissue perfusion and aid in the delivery of insulin to target organs. Insulin administration is essential in the treatment and is initiated immediately, unless there is evidence of severe hypovolaemia or hypokalaemia. Insulin therapy lowers the serum glucose concentration primarily by decreasing hepatic glucose production rather than enhancing peripheral utilisation (<LINK REF="REF-Luzi-1988" TYPE="REFERENCE">Luzi 1988</LINK>), diminishes ketone production (by reducing both lipolysis and glucagon secretion), and may augment ketone clearance. Insulin administration seeks to restore normal glucose uptake by cells; however, excessive insulin administration must be avoided to prevent hypoglycaemia and hypokalaemia.</P>
<P>The route of administration of insulin in the management of DKA has been debated since the early 1970s. <LINK REF="REF-Alberti-1973" TYPE="REFERENCE">Alberti 1973</LINK> reported the results of low-dose intramuscular insulin in the management of people with DKA. They found that an initial average bolus dose of 16 units followed by 5 to 10 units of intramuscular regular insulin per hour was effective in correcting hyperglycaemia and acidaemia. Later in the 1970s, Fisher and colleagues reported a greater decline in blood glucose and ketone body levels in the first two hours of therapy with intravenous insulin as compared to intramuscular or subcutaneous insulin (<LINK REF="STD-Fisher-1977" TYPE="STUDY">Fisher 1977</LINK>). Furthermore, the dehydration and shock state of people with DKA leads to erratic and unpredictable absorption of intramuscular and subcutaneous insulin (<LINK REF="STD-Fisher-1977" TYPE="STUDY">Fisher 1977</LINK>). Based on this finding, it is now generally accepted that continuous intravenous infusion is the most effective route of insulin administration (<LINK REF="REF-Savage-2011" TYPE="REFERENCE">Savage 2011</LINK>).</P>
<P>Randomised controlled trials in people with DKA have shown insulin therapy to be effective regardless of the administration route. Treatment with subcutaneous rapid-acting insulin analogues administered every one to two hours has been shown to be an effective alternative to the use of intravenous regular insulin in the treatment of uncomplicated DKA (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). In one of these trials, the authors found that the effects in people treated with subcutaneous insulin lispro were comparable with those treated with intravenous regular insulin. The authors observed similar rates of death, length of hospital stay, and amount of insulin used until resolution of DKA between treatment groups. Treatment of DKA in the ICU was associated with 39% higher hospitalisation charges than was treatment with subcutaneous lispro in a non-intensive care setting (<LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects of the intervention</HEADING>
<P>Hypoglycaemia is an inherent adverse effect of insulin treatment. Additionally, insulin therapy is associated with injection site reactions, generalised sensitivity reactions, and electrolyte imbalances such as hypokalaemia. Concern has been raised regarding potential mitogenic effects of insulin analogues, but evidence is controversial (<LINK REF="REF-Hemkens-2009" TYPE="REFERENCE">Hemkens 2009</LINK>; <LINK REF="REF-Kurtzhals-2000" TYPE="REFERENCE">Kurtzhals 2000</LINK>). Insulin lispro and insulin aspart, like human insulin, are rated category B for pregnancy use, which means that well-controlled trials in pregnant women are lacking, while insulin glulisine is category C, because only animal reproduction studies have been performed with it (<LINK REF="REF-Home-2012" TYPE="REFERENCE">Home 2012</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>In the last decade, considerable attention has been devoted to the development of insulin analogues with pharmacokinetic profiles that differ from existing insulin preparations. Compared to regular human insulin, proline at position 28 and lysine at position 29 of the B-region were interchanged in the short-acting insulin analogue lispro. In the short-acting insulin analogue aspart, proline at position 28 of the B-region was replaced by aspartic acid, and in the short-acting insulin analogue glulisine, the amino acid asparagine was replaced by lysine at position three and lysine with glutamic acid at position 29 of the B-chain (<LINK REF="REF-Siebenhofer-2006" TYPE="REFERENCE">Siebenhofer 2006</LINK>). Insulin lispro, insulin aspart, and insulin glulisine have very similar pharmacokinetic profiles. These analogues are present either in a monomeric form or a very weakly bound hexameric form. Following subcutaneous injection, they are rapidly absorbed in less than 30 minutes, with a short peak time of insulin concentration of 1 hour and a shorter duration of action of 3 to 4 hours when compared with regular human insulin (<LINK REF="REF-Roach-2008" TYPE="REFERENCE">Roach 2008</LINK>).</P>
<P>Data on rapid-acting insulin analogues in clinical trials (not in DKA) suggest lower postprandial glucose variations when compared with meal-time human insulin in adults and children, and in type 1 and type 2 diabetes (<LINK REF="REF-Home-2000" TYPE="REFERENCE">Home 2000</LINK>; <LINK REF="REF-Mathiesen-2007" TYPE="REFERENCE">Mathiesen 2007</LINK>; <LINK REF="REF-Rayman-2007" TYPE="REFERENCE">Rayman 2007</LINK>). The decreased incidence of major hypoglycaemia requiring third-party assistance, in particular major nocturnal hypoglycaemia, is the expected consequence of the shorter subcutaneous availability time of rapid-acting insulin analogues. In people with type 1 diabetes, the median incidence of severe hypoglycaemia for rapid-acting analogues is 21.8 episodes per 100 person-years compared with 46.1 episodes for human insulin (<LINK REF="REF-Siebenhofer-2006" TYPE="REFERENCE">Siebenhofer 2006</LINK>). In people with type 2 diabetes, the median incidence is 0.3 episodes per 100 person-years for analogues compared with a mean of 1.4 episodes per 100 person-years for human insulin (<LINK REF="REF-Siebenhofer-2006" TYPE="REFERENCE">Siebenhofer 2006</LINK>).</P>
<P>The pharmacokinetic profile of rapid-acting analogues following subcutaneous injection suggests that they might be a feasible alternative in the case of DKA, that is faster rise in plasma concentration, higher peak concentration, and shorter subcutaneous residence time than unmodified human insulin (<LINK REF="REF-Howey-1995" TYPE="REFERENCE">Howey 1995</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>As an alternative to an intravenous infusion of regular insulin, people with mild to moderate DKA can be treated with subcutaneous rapid-acting insulin analogues, offering an opportunity to avoid costly admissions (<LINK REF="REF-Kitabchi-2009" TYPE="REFERENCE">Kitabchi 2009</LINK>; <LINK REF="REF-Nyenwe-2011" TYPE="REFERENCE">Nyenwe 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Delivery of care without constant patient monitoring (for example outside ICU settings) will undoubtedly reduce cost. Also, stable patients could be treated in a step-down unit close to their relatives.</P>
<P>Two systematic reviews comparing rapid-acting insulin analogues with intravenous infusion of regular insulin in the treatment of mild to moderate DKA have been published (<LINK REF="REF-Mazer-2009" TYPE="REFERENCE">Mazer 2009</LINK>; <LINK REF="STD-Vincent-2013" TYPE="STUDY">Vincent 2013</LINK>). Both reviews provide an overview of the studies located, however there are some limitations. Firstly, the comprehensiveness of systematic literature searches was suboptimal. The literature search in Vincent 2013 was restricted exclusively to the PubMed database. Secondly, assessments of risk of bias of studies were not specified (<LINK REF="REF-Mazer-2009" TYPE="REFERENCE">Mazer 2009</LINK>; <LINK REF="STD-Vincent-2013" TYPE="STUDY">Vincent 2013</LINK>).</P>
<P>Given the limitations of previous systematic reviews, we plan to use specific methodology and criteria outlined by Cochrane in our aim to present a comprehensive systematic review to assess the efficacy and safety of subcutaneous rapid-acting insulin analogues in the treatment of DKA in adults and children.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-04-15 05:44:59 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the effects of subcutaneous rapid-acting insulin analogues for the treatment of diabetic ketoacidosis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-01-20 10:41:21 +0100" MODIFIED_BY="Gudrun Paletta">
<SELECTION_CRITERIA MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<CRIT_STUDIES MODIFIED="2016-01-18 14:14:54 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We included randomised controlled trials (RCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We included trials evaluating participants with diabetic ketoacidosis (DKA) of any age or sex with type 1 or type 2 diabetes, and pregnant women (including gestational diabetes).</P>
<P>
<B>Diagnostic criteria for diabetes mellitus</B>
</P>
<P>In order to be consistent with changes in classification and diagnostic criteria of diabetes mellitus over the years, we used the diagnostic criteria valid at the time of the trial commencing (for example <LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>; <LINK REF="REF-ADA-2008" TYPE="REFERENCE">ADA 2008</LINK>; <LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). We used the study authors' definition of diabetes mellitus if necessary. We planned to subject diagnostic criteria to a sensitivity analysis.</P>
<P>
<B>Diagnostic criteria for diabetic ketoacidosis</B>
</P>
<P>We used the American Diabetes Association criteria for DKA (<LINK REF="REF-ADA-2004" TYPE="REFERENCE">ADA 2004</LINK>), which are as follows.</P>
<UL>
<LI>Mild DKA: plasma glucose &gt; 250 mg/dL, arterial pH 7.25 to 7.30, serum bicarbonate 15 to 18 mEq/L, urine and serum ketones positive, anion gap &gt; 10, alteration in sensoria or mental obtundation as alert.</LI>
<LI>Moderate DKA: plasma glucose &gt; 250 mg/dL, arterial pH 7.00 to 7.24, serum bicarbonate 10 to &lt; 15 mEq/L, urine and serum ketones positive, anion gap &gt; 12, alteration in sensoria or mental obtundation as alert/drowsy.</LI>
<LI>Severe DKA: plasma glucose &gt; 250 mg/dL, arterial pH &lt; 7.00, serum bicarbonate &lt; 10 mEq/L, urine and serum ketones positive, anion gap &gt; 12, alteration in sensoria or mental obtundation as stupor/coma.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We planned to investigate the effects of subcutaneous rapid-acting insulin analogues versus standard intravenous infusion of regular insulin. We expected insulin regimens (use of intravenous bolus, dose, and frequency) to vary depending on the study, therefore we accepted all insulin regimens.</P>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<UL>
<LI>Subcutaneous rapid-acting insulin analogues (insulin lispro, insulin aspart, or insulin glulisine).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparator</HEADING>
<UL>
<LI>Intravenous infusion of regular insulin.</LI>
</UL>
<P>Concomitant interventions had to be the same in the intervention and comparator groups to establish fair comparisons.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>Time to resolution of DKA.</LI>
<LI>All-cause mortality.</LI>
<LI>Hypoglycaemic episodes.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>Morbidity.</LI>
<LI>Adverse events other than hypoglycaemia.</LI>
<LI>Patient satisfaction.</LI>
<LI>Glycosylated haemoglobin A1c (HbA1c).</LI>
<LI>Socioeconomic effects.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Method and timing of outcome measurement</HEADING>
<UL>
<LI>Time to resolution of DKA: defined as time to reach blood glucose levels &lt; 200 mg/dL and two of the following criteria: a serum bicarbonate level &#8805; 15 mEq/L, a venous pH &gt; 7.3, and a calculated anion gap &#8804; 12 mEq/L (<LINK REF="REF-Kitabchi-2009" TYPE="REFERENCE">Kitabchi 2009</LINK>).</LI>
<LI>All-cause mortality: defined as the total number of deaths from any cause and measured as in-hospital mortality and 30-day all-cause mortality.</LI>
<LI>Hypoglycaemic episodes: defined as a symptomatic or asymptomatic event with plasma glucose &#8804; 70 mg/dL (3.9 mmol/L) or according to authors' definition.</LI>
<LI>Morbidity: such as cerebral oedema defined by diagnostic criteria, including abnormal motor or verbal responses to pain, decorticate posture, and abnormal neurogenic respiratory patterns (major, but not diagnostic criteria include altered mentation, sustained heart rate decelerations, and age-inappropriate incontinence; minor criteria include vomiting, headache, lethargy, diastolic blood pressure &gt; 90 mm Hg, and age &lt; 5 years (<LINK REF="REF-Muir-2004" TYPE="REFERENCE">Muir 2004</LINK>)).</LI>
<LI>Adverse events other than hypoglycaemia: such as hypokalaemia defined as a serum potassium concentration &lt; 3.5 mEq/L, and injection site reactions.</LI>
<LI>Patient satisfaction: evaluated with a validated instrument such as the Insulin Treatment Satisfaction Questionnaire (<LINK REF="REF-Anderson-2004" TYPE="REFERENCE">Anderson 2004</LINK>).</LI>
<LI>HbA1c: measured at hospital admission (baseline) and at three months postdischarge.</LI>
<LI>Socioeconomic effects: such as length of hospital stay, calculated by subtracting day of admission from day of discharge, and costs, measured as data on hospital charges.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">'Summary of findings' table</HEADING>
<P>We present a 'Summary of findings' table reporting the following outcomes listed according to priority.</P>
<OL>
<LI>All-cause mortality.</LI>
<LI>Hypoglycaemic episodes.</LI>
<LI>Morbidity.</LI>
<LI>Adverse events other than hypoglycaemic episodes.</LI>
<LI>Time to resolution of DKA.</LI>
<LI>Patient satisfaction.</LI>
<LI>Socioeconomic effects.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-01-20 10:41:21 +0100" MODIFIED_BY="Gudrun Paletta">
<ELECTRONIC_SEARCHES MODIFIED="2016-01-20 10:41:21 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We searched the following sources from inception of each database to the specified date and placed no restrictions on the language of publication.</P>
<UL>
<LI>Cochrane Library (27 October 2015)</LI>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 9, September 2015)</LI>
<LI>Database of Abstracts of Reviews of Effects (DARE) (Issue 2, April 2015)</LI>
<LI>Health Technology Assessment (HTA) Database (Issue 3, July 2015)</LI>
</UL>
<LI>Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R) (1946 to 27 October 2015)</LI>
<LI>PubMed (segments not available on Ovid) (27 October 2015)</LI>
<LI>EMBASE (1974 to 26 October 2015)</LI>
<LI>LILACS (23 October 2015)</LI>
<LI>CINAHL (27 October 2015)</LI>
<LI>ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</A>, 27 October 2015)</LI>
<LI>WHO ICTRP Search Portal (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>) (27 October 2015):</LI>
<UL>
<LI>Australian New Zealand Clinical Trials Registry (19 October 2015)</LI>
<LI>Chinese Clinical Trial Registry (19 October 2015)</LI>
<LI>ClinicalTrials.gov (19 October 2015)</LI>
<LI>EU Clinical Trials Register (EU-CTR) (19 October 2015)</LI>
<LI>ISRCTN (19 October 2015)</LI>
<LI>The Netherlands National Trial Register (19 October 2015)</LI>
<LI>Brazilian Clinical Trials Registry (ReBec) (13 October 2015)</LI>
<LI>Clinical Trials Registry - India (13 October 2015)</LI>
<LI>Clinical Research Information Service - Republic of Korea (13 October 2015)</LI>
<LI>Cuban Public Registry of Clinical Trials (13 October 2015)</LI>
<LI>German Clinical Trials Register (13 October 2015)</LI>
<LI>Iranian Registry of Clinical Trials (4 August 2015)</LI>
<LI>Japan Primary Registries Network (19 October 2015)</LI>
<LI>Pan African Clinical Trial Registry (13 October 2015)</LI>
<LI>Sri Lanka Clinical Trials Registry (13 October 2015)</LI>
<LI>Thai Clinical Trials Register (TCTR) (13 October 2015)</LI>
</UL>
</UL>
<P>We continuously applied a MEDLINE (via Ovid) email alert service to identify newly published studies using the same search strategy as described for MEDLINE (for details on search strategies see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). After supplying the final review draft for editorial approval, the Cochrane Metabolic and Endocrine Disorders Group performed a complete updated search on all databases available at the editorial office and sent the results to the review authors. Should we have identified new trials for inclusion, we evaluated these, incorporated the findings into our review, and resubmitted another review draft (<LINK REF="REF-Beller-2013" TYPE="REFERENCE">Beller 2013</LINK>).</P>
<P>We planned to evaluate any newly identified studies for inclusion, incorporate the findings into our review, and resubmit another review draft (<LINK REF="REF-Beller-2013" TYPE="REFERENCE">Beller 2013</LINK>).</P>
<P>If we detected additional relevant key words during any of the electronic or other searches, we would have modified the electronic search strategies to incorporate these terms and document the changes to the search strategy.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We attempted to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, (systematic) reviews, meta-analyses, and health technology assessment reports.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_SELECTION MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Two review authors (CAC, LCL) independently reviewed the abstract, title, or both, of every record retrieved in order to determine which trials should be assessed further. We investigated all potentially relevant articles as full text. We resolved any discrepancies through consensus or recourse to a third review author (NDF). If resolution of a disagreement was not possible, we planned to add the article to those 'awaiting assessment', and we would have contacted study authors for clarification. We have presented an adapted Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing the process of trial selection (<LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>For trials that fulfilled our inclusion criteria, two review authors (CAC, LCL) independently abstracted relevant population and intervention characteristics using standard data extraction templates (for details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5;</LINK> <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>; <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>; <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>; <LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>; <LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK>; <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>), with any disagreements to be resolved by discussion, or, if required, by a third review author (NDF).</P>
<P>We have provided information including trial identifier about potentially relevant ongoing trials in <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> and in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> ('Matrix of study endpoints (publications and trial documents)'). We attempted to identify the protocol of each included trial, either in trials registers, publications of study designs, or both, and specified data in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</P>
<P>We emailed authors of included trials to enquire as to whether they would be willing to answer questions regarding their trials. <LINK REF="APP-13" TYPE="APPENDIX">Appendix 13</LINK> shows the results of this survey. We thereafter sought relevant missing information on the trial from the primary author(s) of the article, if required.</P>
<P>
<B>Dealing with duplicate and companion publications</B>
</P>
<P>In the event of duplicate publications, companion documents, or multiple reports of a primary trial, we maximised yield of information by collating all available data and using the most complete data set aggregated across all known publications. Where unclear, the publication reporting the longest follow-up associated with our primary or secondary outcomes obtained priority. We listed duplicate publications, companion documents or multiple reports of a primary trial as secondary references under the study ID of the included or excluded trial.<BR/>
</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Two review authors (CAC, NDF) independently assessed the risk of bias of each included trial. We resolved disagreements by consensus, or by consultation with a third review author (DGP).</P>
<P>We assessed risk of bias using the tool of The Cochrane Collaboration (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). We used the following criteria.</P>
<UL>
<LI>Random sequence generation (selection bias).</LI>
<LI>Allocation concealment (selection bias).</LI>
<LI>Blinding of participants and personnel (performance bias).</LI>
<LI>Blinding of outcome assessment (detection bias).</LI>
<LI>Incomplete outcome data (attrition bias).</LI>
<LI>Selective reporting (reporting bias).</LI>
<LI>Other potential sources of bias.</LI>
</UL>
<P>We judged 'Risk of bias' criteria as 'low risk', 'high risk', or 'unclear risk' and evaluated individual bias items as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). We have presented a 'Risk of bias' graph and a 'Risk of bias summary'. We assessed the impact of individual bias domains on trial results at the endpoint and trial levels. In case of high risk of selection bias, we would have marked all endpoints investigated in the associated trial as 'high risk'.</P>
<P>For performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessors), we evaluated the risk of bias separately for each outcome (<LINK REF="REF-Hr_x00f3_bjartsson-2013" TYPE="REFERENCE">Hróbjartsson 2013</LINK>). We noted whether outcomes were measured subjectively or objectively, for example if body weight was measured by participants or trial personnel.</P>
<P>We considered the implications of missing outcome data from individual participants per outcome such as high drop-out rates (for example above 15%) or disparate attrition rates (for example difference of 10% or more between trial arms).</P>
<P>We assessed outcome reporting bias by integrating the results of 'Examination of outcome reporting bias' (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) and 'Matrix of study endpoints (publications and trial documents)' (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) (<LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>). This analysis formed the basis for the judgement of selective reporting (reporting bias).</P>
<P>We defined the following endpoints as subjective outcome measures.</P>
<UL>
<LI>Patient satisfaction.</LI>
<LI>Hypoglycaemic episodes, depending on measurement.</LI>
<LI>Adverse events other than hypoglycaemia, depending on measurement.</LI>
</UL>
<P>We defined the following endpoints as objective outcome measures.</P>
<UL>
<LI>Time to resolution of DKA.</LI>
<LI>All-cause mortality.</LI>
<LI>Morbidity.</LI>
<LI>Hypoglycaemic episodes, depending on measurement.</LI>
<LI>Adverse events other than hypoglycaemia, depending on measurement.</LI>
<LI>HbA1c.</LI>
<LI>Socioeconomic effects.</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We expressed dichotomous data as odds ratios or risk ratios with 95% confidence intervals (CIs). We expressed continuous data as mean differences with 95% CIs. We planned to express time-to-event data as hazard ratios with 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We took into account the level at which randomisation occurred, such as cross-over trials, cluster-randomised trials, and multiple observations for the same outcome.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We obtained missing data from authors, if feasible, and carefully evaluated important numerical data such as screened, randomised participants as well as intention-to-treat and as-treated and per-protocol populations. We investigated attrition rates, (e.g. drop-outs, losses to follow-up, withdrawals), and we will critically appraise issues concerning missing data and imputation methods (e.g. last observation carried forward (LOCF)).</P>
<P>Where standard deviations for outcomes were not reported and we did not receive information from trial authors, we planned to impute these values by assuming the standard deviation of the missing outcome to be the average of the standard deviations from those studies where this information was reported. We wanted to investigate the impact of imputation on meta-analyses by means of sensitivity analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>In the event of substantial clinical or methodological heterogeneity, we did not report trial results as the pooled effect estimate in a meta-analysis.</P>
<P>We identified heterogeneity (inconsistency) through visual inspection of the forest plots and by using a standard Chi² test with a significance level of &#945; = 0.1. In view of the low power of this test, we also considered the I² statistic, which quantifies inconsistency across trials to assess the impact of heterogeneity on the meta-analysis (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>); an I² statistic of 75% or more indicates a considerable level of heterogeneity (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<P>Had we found heterogeneity, we would have attempted to determine possible reasons for it by examining individual trial and subgroup characteristics.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Had we included 10 trials or more investigating a particular outcome, we would have used funnel plots to assess small-study effects. Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias. We therefore planned to interpret results carefully (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Unless there was good evidence for homogeneous effects across studies, we primarily summarised low risk of bias data by means of a random-effects model (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). We interpreted random-effects meta-analyses with due consideration of the whole distribution of effects, ideally by presenting a prediction interval (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>), which specifies a predicted range for the true treatment effect in an individual study (<LINK REF="REF-Riley-2011" TYPE="REFERENCE">Riley 2011</LINK>). In addition, we performed statistical analyses according to the statistical guidelines presented in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<P>
<B>Quality of evidence</B>
</P>
<P>We have presented the overall quality of the evidence for each outcome according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, which takes into account issues not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results<I>. </I>Two review authors (CAC, NDF) independently rated the quality for each outcome. We have presented a summary of the evidence in 'Summary of findings' (SoF) tables, which provide key information about the best estimate of the magnitude of the effect, in relative terms and absolute differences for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome, and the rating of the overall confidence in effect estimates for each outcome. We created the SoF tables based on the methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>by means of the table editor in Review Manager (RevMan), including <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK> 'Checklist to aid consistency and reproducibility of GRADE assessments' to help with standardisation of the 'Summary of findings' tables (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Meader-2014" TYPE="REFERENCE">Meader 2014</LINK>; <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). Alternatively, we used the GRADEproGDT software and present evidence profile tables as an appendix (GRADEproGDT 2015). We have presented results on the outcomes as described in the <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK> section. If meta-analysis was not possible, we presented results in a narrative form in the SoF table.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-12-15 18:49:40 +0100" MODIFIED_BY="Bernd Richter">
<P>We expected the following characteristics to introduce clinical heterogeneity, and planned to carried out subgroup analyses with investigation of interactions.<BR/>
</P>
<UL>
<LI>Age.</LI>
<LI>Pregnancy.</LI>
<LI>Comorbidities.</LI>
<LI>Precipitating factors (infection, poor adherence to diabetes treatment).</LI>
<LI>Severity of DKA episode (mild, moderate, severe).</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-01-18 16:14:24 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting the analysis to the following.<BR/>
</P>
<UL>
<LI>Published trials.</LI>
<LI>Taking into account risk of bias, as specified in the <LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK> section.</LI>
<LI>Very long or large trials to establish the extent to which they dominate the results.</LI>
<LI>Trials using the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry versus other), or country.</LI>
</UL>
<P>We also tested the robustness of the results by repeating the analysis using different measures of effect size (RR, OR, etc.) and different statistical models (fixed-effect and random-effects models).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-01-20 10:40:52 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_DESCRIPTION MODIFIED="2016-01-20 10:40:52 +0100" MODIFIED_BY="Gudrun Paletta">
<P>For a detailed description of the included trials, see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies,</LINK> and <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The electronic search strategies retrieved a total of 645 citations. After duplicates were excluded, two review authors (CAC, LCL) independently assessed the remaining titles and abstracts. We obtained the full text of 23 potentially relevant trials, seven of which we deemed potentially appropriate for inclusion in the analysis. Of these, two trials are awaiting classification, one trial was published as an abstract only, and another trial was registered in ClinicalTrials.gov with the status "This study has been completed", but no trial results were posted and no publication is available. We have provided information about these trials in <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>.</P>
<P>We have provided an adapted PRISMA flowchart of study selection, see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-01-20 10:40:52 +0100" MODIFIED_BY="Gudrun Paletta">
<P>For a detailed description of the included studies, see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. The following is a succinct overview.</P>
<P>
<B>Source of data</B>
</P>
<P>A total of five trials (five publications) met the inclusion criteria. All five included trials were published as peer-reviewed original articles. All articles were published in English. We found no eligible trials from before the year 2004.</P>
<P>
<B>Comparisons</B>
</P>
<P>All five included trials investigated the effects of a subcutaneous rapid-acting insulin analogues compared with intravenous regular insulin. Four trials used lispro (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>), and one used aspart as a rapid acting insulin analogue (<LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). No trial applied glulisine.</P>
<P>
<B>Overview of study populations</B>
</P>
<P>The included trials evaluated a total of 201 participants, of which 110 received a subcutaneous rapid-acting insulin analogue and 91 received intravenous regular insulin. All randomised participants finished their assigned treatment.</P>
<P>
<B>Study design</B>
</P>
<P>All included randomised controlled trials were of a parallel design and were performed in a single study centre. All trials compared a subcutaneous rapid-acting insulin analogue with intravenous regular insulin in an open-label fashion until resolution of the DKA episode. No trials specified blinding of outcome assessors. Trials were published from 2004 to 2011. Two trials were partly or entirely sponsored by the pharmaceutical industry (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>).</P>
<P>
<B>Settings</B>
</P>
<P>Trials were conducted in the USA (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>), Brazil (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>), Turkey (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>), and India (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for details). In the US and Brazilian trials, participants were treated with subcutaneous insulin managed in regular medicine wards, in <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK> and <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>, or in the emergency department, in <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>, and the participants treated with intravenous insulin were managed in the intensive care unit (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Two trials stated that the participants were managed in the emergency department (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>), and the Turkish trial did not provide details about the setting (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>).</P>
<P>
<B>Participants</B>
</P>
<P>A total of 201 participants were randomised and exposed to trial insulins in the included studies. All five trials recruited people who had a DKA episode (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). One trial included paediatric and adolescent participants (60 DKA episodes in 46 participants) with a median age of 11 years (range 3 to 17 years) (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>); the other trials included either type 1 or type 2 diabetic adults with a DKA episode (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). No trial specified the number of participants or percentages of participants with either type of diabetes. Three trials reported duration of diabetes (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>); mean duration of diabetes in these trials ranged between 3.9 and 6.9 years. The mean age of participants ranged between 34 and 49 years in the trials with adults only (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Sixty per cent of participants came from low- to middle-income countries, and 27% to 76% were female. In one of the US trials, around 77% of participants were African American (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>). The other trials did not specify ethnic groups.</P>
<P>Four of the five trials reported a precipitating cause of the DKA episode (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Poor compliance with insulin therapy was the most common precipitating cause (54%). Other precipitating causes reported were infections (31%) and new-onset diabetes (15%). Two trials reported HbA1c at baseline (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Mean HbA1c at baseline in these trials ranged between 11.4% and 13.9%.</P>
<P>All trials listed persistent hypotension as an exclusion criterion, but only the US trials clearly defined this (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Three trials excluded people with acute myocardial ischaemia, end-stage renal disease, anasarca, and pregnancy (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Two trials excluded people with dementia (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>), heart failure (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>), and with American Diabetes Association (ADA) criteria for severe DKA (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>). Other criteria used for excluding participants were surgery, use of glucocorticoid or immunosuppressive agents (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>), and the presence of hepatic failure (<LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>).</P>
<P>
<B>Diagnosis</B>
</P>
<P>All trials specified diagnostic criteria for entry into the study. These criteria were consistent with the ADA criteria for mild or moderate DKA (<LINK REF="REF-ADA-2004" TYPE="REFERENCE">ADA 2004</LINK>). None of the included trials explicitly reported diagnostic criteria for diabetes mellitus.</P>
<P>
<B>Interventions</B>
</P>
<P>None of the included trials reported treatment before the DKA episode. All of the trials compared subcutaneous rapid-acting insulin analogue injections every one to two hours with continuous intravenous infusions of regular insulin. Duration of interventions ranged from DKA diagnosis to DKA resolution.</P>
<P>Intravenous regular insulin regimens varied slightly across the trials. In three trials, the intravenous regular insulin bolus was 0.1 IU/kg, followed by continuous infusion given at 0.1 IU/kg/h until blood glucose decreased to &lt; 250 mg/dL, and then continued at a lower dose (0.05 IU/kg/h until resolution of DKA) (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). <LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK> used a slightly higher bolus dose of intravenous regular insulin of 0.15 IU/kg/h followed by &#8220;standard&#8221; intravenous regular insulin infusion. In the paediatric trial (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>), no bolus was used, and intravenous regular insulin infusion was given at 0.1 IU/kg/h until blood glucose decreased to &lt; 250 mg/dL; thereafter 0.15 IU/kg regular insulin was given subcutaneously 30 minutes before stopping the intravenous line.</P>
<P>Subcutaneous rapid-acting insulin analogues injections varied across studies. Four trials used lispro at given dosages: injection regimens were either 0.15 IU every two hours without bolus (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>), or 0.075 IU/kg every hour, preceded by a bolus injection of intravenous regular insulin (0.15 IU/kg) (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>), or 0.1 IU/kg every hour, preceded by an initial subcutaneous bolus of insulin lispro (0.3 IU/kg) (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>), or initial subcutaneous bolus of insulin lispro (0.3 IU/kg), followed by 0.2 IU/kg one hour later and then 0.2 IU/kg every two hours (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>). One trial used insulin aspart; subcutaneous insulin aspart was given as an initial dose of 0.3 IU/kg, followed by either 0.1 IU/kg every hour (group 1), or 0.2 IU/kg one hour later and every two hours (group 2) (<LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). In one trial, when capillary blood glucose levels neared 250 mg/dL, insulin lispro was administered every four hours for the next 24 hours (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>).</P>
<P>
<B>Concomitant interventions</B>
</P>
<P>Fluid replacement protocols were similar in all included trials. This was largely in agreement with guideline recommendations (<LINK REF="REF-ADA-2004" TYPE="REFERENCE">ADA 2004</LINK>). Isotonic (0.9%) saline was infused at a rate of 10 to 20 mL/kg/h or 500 to 1000 mL/h for the initial one to two hours. Subsequent fluid replacement was adapted depending on the participant&#8217;s overall status and blood glucose levels until resolution of DKA. Potassium replacement was also in agreement with guideline recommendations (<LINK REF="REF-ADA-2004" TYPE="REFERENCE">ADA 2004</LINK>).</P>
<P>
<B>Outcomes</B>
</P>
<P>Three trials did not explicitly specify a primary outcome (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>). Four trials defined DKA by venous pH criteria (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>), and one trial by arterial pH (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>). Four trials used a serum bicarbonate criterion &gt; 18 mmol/L as an endpoint (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). The paediatric trial used a serum bicarbonate criterion &gt; 15 mmol/L (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>). Notably, only one trial clearly stated blood glucose levels &lt; 200 mg/dL as an endpoint (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>).</P>
<P>All trials reported data on adverse events in the form of hypoglycaemic episodes during therapy. Four trials defined the endpoint for this outcome as a plasma glucose &#8804; 60 mg/dL (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). In the trial by <LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>, the outcome measure of hypoglycaemia was not defined. All five trials reported on in-hospital mortality. Three trials reported length of hospital stay (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). The paediatric trial investigated morbidity in the form of cases of cerebral oedema (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>), and <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK> described venous thrombosis, adult respiratory distress syndrome, and hyperchloraemic acidosis events. One trial investigated total costs, measured as data on hospital charges (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>). No trial reported on patient satisfaction, adverse events other than hypoglycaemia, and change of HbA1c from baseline.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We excluded 16 trials after evaluation of the full publication. We have provided reasons for exclusion of studies in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. The main reasons for exclusion were inappropriate interventions and non-randomised study design.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>For details on risk of bias of included trials, see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>For an overview of review authors' judgements about each risk of bias item for individual trials and across all trials, see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Reporting on the methods of randomisation and allocation concealment was poor in most of the trials. All trials were described as randomised, however the method of randomisation was adequately described in only two trials (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). None of the included trials described allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The stated method of blinding was open in all five trials. No trial described blinding of outcome assessors. Given the nature of the interventions, participant and personnel blinding was not appropriate. However, this implied a high risk of performance bias for the outcome measure time to resolution of DKA.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>All five trials reported having complete data for all included participants.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>No study protocol was available for the included trials. Reporting bias was unclear for two trials due to unclear reporting of outcome data for time to resolution of DKA (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-12-16 12:57:30 +0100" MODIFIED_BY="Bernd Richter">
<P>Two publications reported commercial funding (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>), a source of possible sponsor bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<SUBSECTION>
<HEADING LEVEL="3">Baseline characteristics</HEADING>
<P>For details of baseline characteristics, see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subcutaneous rapid-acting insulin analogues versus intravenous infusion of regular insulin</HEADING>
<P>
<LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK> was a three-arm trial investigating intravenous regular insulin versus subcutaneous insulin aspart, given in doses one or two hours apart. In order to avoid a unit of analysis error, we used the one-hour group for all meta-analyses.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Time to resolution of DKA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Lispro versus regular insulin (adults)</HEADING>
<P>Two trials compared subcutaneous insulin lispro with intravenous regular insulin in adults with DKA (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>). Meta-analysis showed the following differences between the two groups: mean difference (MD) 0.2 h (95% confidence interval (CI) -1.7 to 2.1); P = 0.81; 90 participants; 2 trials; very low-quality evidence; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. There was a high risk of performance bias and an unclear risk of detection bias for both included trials (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Lispro versus regular insulin (children)</HEADING>
<P>One trial including 60 children compared subcutaneous insulin lispro with intravenous regular insulin (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>). In both groups, the time to reach a glucose level of 250 mg/dL or less was approximately six hours. However, metabolic acidosis and ketosis took longer to resolve in the subcutaneous insulin lispro group (for intravenous regular insulin the time was six hours after capillary glucose &#8804; 250 mg/dL, and for subcutaneous insulin lispro this occurred "in the next 6-h interval" (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>)). The trial authors concluded that glycaemic control worsened when insulin lispro was spaced to every four hours, indicating that this was time was too long to maintain the insulin analogue action. In addition, children receiving insulin lispro were more likely to receive bicarbonate therapy. There was a high risk of performance bias, an unclear risk of detection bias, and an unclear risk of reporting bias for this included trial (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Aspart versus regular insulin</HEADING>
<P>One trial compared subcutaneous insulin aspart with intravenous regular insulin in an adult population (<LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). There was the following difference between the two groups: MD -1 h (95% CI -3.2 to 1.2); P = 0.36; 30 participants; 1 trial; very low-quality evidence; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>. There was a high risk of performance bias and an unclear risk of detection bias for this included trial (<LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>All five included trials reported that there were no deaths (4 trials with 156 participants evaluating insulin lispro; moderate-quality evidence; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, and 1 trial with 45 participants evaluating insulin aspart (two different insulin aspart schemes in 15 participants each); low-quality evidence; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). However, no trial was adequately powered to investigate all-cause mortality. There was an overall low risk of bias for this outcome measure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypoglycaemic episodes</HEADING>
<P>Information on hypoglycaemia was available from all included trials. Hypoglycaemia was mostly defined as a blood glucose level lower than 60 mg/dL (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). One trial did not provide a definition of hypoglycaemia (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">Lispro versus regular insulin</HEADING>
<P>Four trials reported hypoglycaemic episodes (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>; <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Comparison of insulin lispro versus regular insulin showed a risk ratio (RR) 0.59 (95% CI 0.23 to 1.52); P = 0.28; 156 participants; 4 trials; low-quality evidence; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>. There was a high risk of performance bias and an unclear risk of detection bias for all included trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Aspart versus regular insulin</HEADING>
<P>One trial including 45 participants compared subcutaneous insulin aspart with intravenous regular insulin in an adult population (<LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Insulin aspart versus regular insulin did not show marked differences in the number of hypoglycaemic episodes (1/15 in the insulin aspart given every hour group; 1/15 in the insulin aspart given every two hours group; and 1/15 in the regular insulin group. RR comparing one of the two insulin aspart groups versus the regular insulin group was 1.00 (95% CI 0.07 to 14.55); P = 1.00; 30 participants; 1 trial; low-quality evidence; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>. There was a high risk of performance bias and an unclear risk of detection bias for the included trial.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Morbidity</HEADING>
<P>Two trials investigating the effects of insulin lispro versus regular insulin reported some data on morbidity related to the sequelae of DKA. One paediatric trial reported morbidity in the form of cerebral oedema (<LINK REF="STD-Della-Manna-2005" TYPE="STUDY">Della Manna 2005</LINK>). There were no cases of cerebral oedema, and no child had to be treated with mannitol. <LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK> reported that none of the participants in either group developed complications such as venous thrombosis, adult respiratory distress syndrome, or hyperchloraemic acidosis.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events other than hypoglycaemia</HEADING>
<P>No trials reported adverse events other than hypoglycaemia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Patient satisfaction</HEADING>
<P>No trial reported on patient satisfaction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c</HEADING>
<P>HbA1c values were available in two trials for verification of metabolic control (<LINK REF="STD-Ers_x00f6_z-2006" TYPE="STUDY">Ersöz 2006</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). However, the differences in change of HbA1c from baseline to study endpoint were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Socioeconomic effects</HEADING>
<P>Three of the trials performed in adults reported length of hospital stay (<LINK REF="STD-Karoli-2011" TYPE="STUDY">Karoli 2011</LINK>; <LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>; <LINK REF="STD-Umpierrez--2004b" TYPE="STUDY">Umpierrez 2004b</LINK>). Comparing subcutaneous insulin lispro with intravenous regular insulin resulted in a MD of -0.4 days (95% CI -1 to 0.2); P = 0.22; 90 participants; 2 trials; low-quality evidence; (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) and between subcutaneous insulin aspart and intravenous regular insulin: MD -1.1 day (95% CI -3.3 to 1.1); P = 0.32; 30 participants; 1 trial; low-quality evidence (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>One study addressed costs (<LINK REF="STD-Umpierrez-2004a" TYPE="STUDY">Umpierrez 2004a</LINK>). The study authors calculated that DKA treatment with subcutaneous insulin lispro in the non-intensive care unit setting was associated with 39% lower hospitalisation charges compared with regular insulin treatment in the intensive care unit (USD 8801 (SD USD 5549) versus USD 14,429 (SD USD 5243).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>We did not perform subgroup analyses because there were not enough studies to estimate effects in various subgroups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>We could not perform preplanned analyses excluding unpublished trials because we included only published studies in this review. We were unable to perform sensitivity analyses with regard to risk of bias because all studies were of high or unclear risk of bias in various domains.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting bias</HEADING>
<P>We did not draw funnel plots due to limited number of studies (n = 5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We did not identify ongoing randomised controlled trials.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<SUMMARY_OF_RESULTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>This systematic review analysed the evidence from all published randomised controlled trials (RCTs) of subcutaneous rapid-acting insulin analogues in the treatment of diabetic ketoacidosis (DKA). We included five trials with a total of 201 participants in this review. The results of our review suggest that there is no substantial difference in the time to resolution of DKA between the subcutaneous rapid-acting insulin analogues lispro or aspart and intravenous regular insulin in adult participants. In the one included trial that assessed the effects of insulin lispro in children and adolescents with DKA, the resolution of acidaemia took longer as compared to intravenous regular insulin; the authors attributed this slower resolution to the increased interval of injections at every four hours after the initial decline of blood glucose to less than 250 mg/dL.</P>
<P>In terms of hypoglycaemia and length of hospital stay, the results obtained with subcutaneous rapid-acting insulin analogues and regular insulin were comparable in both adults and children. No deaths occurred. Data on morbidity and socioeconomic effects were limited. None of the trials reported on adverse events other than hypoglycaemia, patient satisfaction, or glycosylated haemoglobin A1c.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The trials analysed in this review were conducted in four different countries, three of which could be considered as low- or middle-income countries. Notably, most participants representing the high-income Western region were of African-American ethnicity. Younger diabetic participants and children were underrepresented in our trial cohorts. Based on the inclusion criteria of the analysed trials, the results are most relevant to adults with a mild or moderate DKA episode due to poor compliance with diabetes therapy. This may reflect poor 'health literacy' and lack of comprehension of treatment plans, factors associated with socioeconomic deprivation in low- or middle-income countries. Regarding the interventions, rapid-acting insulin analogues like insulin lispro and insulin aspart are widely available for use in daily clinical practice.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The risk of bias across several domains was unclear for the majority of included studies. This was due mainly to there being insufficient information to permit judgement of either a low or high risk of bias, despite attempts to contact the trial authors. According to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the quality of the evidence was low or very low for most clinically important outcomes (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The available data were thus too few and inconsistent to provide firm evidence about the effects of subcutaneous rapid-acting insulin analogues in people with DKA.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We conducted our review according to the previously published protocol. Two review authors independently assessed all citations identified by our electronic search strategies. Likewise, two review authors conducted 'Risk of bias' assessment and data collection. There were no conflicts of interests.</P>
<P>We believe that our search for RCTs has been comprehensive. However, we cannot exclude the possibility that studies with negative findings remain unpublished. Also, we did not systematically search the grey literature.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Our systematic review on subcutaneous rapid-acting insulin analogues for DKA is in agreement with previously published reviews, <LINK REF="REF-Mazer-2009" TYPE="REFERENCE">Mazer 2009</LINK> and <LINK REF="STD-Vincent-2013" TYPE="STUDY">Vincent 2013</LINK>, and current guidelines on the management of a hyperglycaemic crisis in adults with diabetes; treatment with subcutaneous rapid-acting insulin analogues (lispro and aspart) appears as an alternative to the use of intravenous regular insulin in the treatment of mild and moderate DKA (<LINK REF="REF-Kitabchi-2009" TYPE="REFERENCE">Kitabchi 2009</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<IMPLICATIONS_PRACTICE MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Our analyses suggest that, on the basis of mostly low- to very low-quality evidence, there are neither advantages nor disadvantages when comparing the effects of subcutaneous rapid-acting insulin analogues (insulin lispro, insulin aspart) versus intravenous regular insulin for treating DKA. These results are most relevant to adults with a mild or moderate DKA episode due to poor compliance with diabetes therapy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Due to the paucity of high-quality evidence from RCTs comparing insulin interventions for DKA, future trials have the potential to change our way of treating this debilitating and expensive condition.</P>
<P>Future RCTs should adequately report on the method of randomisation and treatment allocation concealment. Blinding of study participants, study personnel, and outcome assessors could be done by using double-dummy designs. Follow-up of participants should be longer, and trial authors should adhere to the intention-to-treat principle. In addition, outcome measures should include patient satisfaction, morbidity, and socioeconomic effects. Finally, multicentre trials are desirable to ensure external validity.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We thank Karla Bergerhoff and Maria-Inti Metzendorf, Trials Search Co-ordinators of the Cochrane Metabolic and Endocrine Disorders Group, for developing the electronic search strategies.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-01-18 15:10:10 +0100" MODIFIED_BY="Gudrun Paletta">
<P>CAC: none known.</P>
<P>LCL: none known.</P>
<P>NDF: none known.</P>
<P>DGP: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-01-18 15:08:57 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Carlos A Andrade-Castellanos (CAC): protocol drafting, acquiring trial reports, trial selection, data extraction, data analysis, data interpretation.</P>
<P>Luis E Colunga-Lozano (LCL): acquiring trial reports, trial selection, data extraction, data analysis, data interpretation, review drafting, and future review updates.</P>
<P>Netzahualpilli Delgado-Figueroa (NDF): protocol drafting, acquiring trial reports, data analysis, data interpretation, review drafting, and future review updates.</P>
<P>Daniel A Gonzalez-Padilla (DGP): acquiring trial reports, data analysis, review drafting, and future review updates.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2016-01-18 15:08:13 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We have based parts of the background, the methods section, appendices, additional tables and figures 1 to 3 of this review on a standard template established by the CMED Group.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDIES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<INCLUDED_STUDIES MODIFIED="2015-10-15 11:02:09 +0200" MODIFIED_BY="Bernd Richter">
<STUDY DATA_SOURCE="PUB" ID="STD-Della-Manna-2005" MODIFIED="2015-03-05 10:56:04 +0100" MODIFIED_BY="[Empty name]" NAME="Della Manna 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-03-05 10:56:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Della Manna T, Steinmetz L, Campos PR, Farhat SC, Schvartsman C, Kuperman H, et al</AU>
<TI>Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1856-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ers_x00f6_z-2006" MODIFIED="2015-03-05 10:56:15 +0100" MODIFIED_BY="[Empty name]" NAME="Ersöz 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-03-05 10:56:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ersöz HO, Ukinc K, Köse M, Erem C, Gunduz A, Hacihasanoglu AB, et al</AU>
<TI>Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2006</YR>
<VL>60</VL>
<NO>4</NO>
<PG>429-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karoli-2011" MODIFIED="2014-10-17 16:31:12 +0200" MODIFIED_BY="[Empty name]" NAME="Karoli 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-10-17 16:31:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karoli R, Fatima J, Salman T, Sandhu S, Shankar R</AU>
<TI>Managing diabetic ketoacidosis in non-intensive care unit setting: Role of insulin analogs</TI>
<SO>Indian Journal of Pharmacology</SO>
<YR>2011</YR>
<VL>43</VL>
<NO>4</NO>
<PG>398-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Umpierrez-2004a" MODIFIED="2015-10-15 11:02:09 +0200" MODIFIED_BY="Bernd Richter" NAME="Umpierrez 2004a" YEAR="2004">
<REFERENCE MODIFIED="2015-03-05 10:56:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, et al</AU>
<TI>Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>117</VL>
<NO>5</NO>
<PG>291-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Umpierrez--2004b" MODIFIED="2014-10-17 16:22:50 +0200" MODIFIED_BY="[Empty name]" NAME="Umpierrez  2004b" YEAR="2004">
<REFERENCE MODIFIED="2014-10-17 16:22:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE</AU>
<TI>Treatment of diabetic ketoacidosis with subcutaneous insulin aspart</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>8</NO>
<PG>1873-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY DATA_SOURCE="PUB" ID="STD-Adesina-2011" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Adesina 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adesina OF, Kolawole BA, Ikem RT, Adebayo OJ, Soyoye DO</AU>
<TI>Comparison of lispro insulin and regular insulin in the management of hyperglycaemic emergencies</TI>
<SO>African Journal of Medicine and Medical Sciences</SO>
<YR>2011</YR>
<VL>40</VL>
<PG>59-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Armor-2011" MODIFIED="2015-04-03 02:09:12 +0200" MODIFIED_BY="[Empty name]" NAME="Armor 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-04-03 02:09:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armor B, Harrison D, Lawler F</AU>
<TI>Assessment of the clinical outcome of a symptom-based outpatient hyperglycemia protocol</TI>
<SO>Diabetes Therapy</SO>
<YR>2011</YR>
<VL>2</VL>
<PG>67-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Attia-1998" MODIFIED="2015-03-05 10:56:37 +0100" MODIFIED_BY="[Empty name]" NAME="Attia 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-03-05 10:56:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attia N, Jones TW, Holcombe J, Tamborlane WV</AU>
<TI>Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>5</VL>
<PG>817-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisher-1977" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Fisher 1977" YEAR="1977">
<REFERENCE MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fisher JN, Shahshahani MN, Kitabchi AE</AU>
<TI>Diabetic ketoacidosis: low-dose insulin therapy by various routes</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1977</YR>
<VL>297</VL>
<NO>5</NO>
<PG>238-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsia-2011" MODIFIED="2015-03-05 10:56:45 +0100" MODIFIED_BY="[Empty name]" NAME="Hsia 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-03-05 10:56:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsia E, Seggelke S, Draznin B</AU>
<TI>Novel insulin infusion protocol: Subcutaneous administration of long-acting insulin during insulin infusion prevents rebound hyperglycemia</TI>
<SO>Diabetes</SO>
<YR>2011</YR>
<VL>60</VL>
<PG>A262</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kadowaki-2010" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Kadowaki 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kadowaki T, Nishida T, Kaku K</AU>
<TI>28-week, randomised, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes</TI>
<SO>Journal of Diabetes Investigation</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>3</NO>
<PG>103-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu J, Jia Z, Zhang B, Hong LV, Zhang G, Tan B, et al</AU>
<TI>Insulin pump in the treatment of diabetic ketoacidosis</TI>
<SO>Chinese Journal of Emergency Medicine</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>460-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00467246" MODIFIED="2016-01-19 12:52:07 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00467246" YEAR="2007">
<REFERENCE MODIFIED="2016-01-19 12:51:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00467246</AU>
<TI>Sub-cutaneous insulin in hyperglycaemic emergencies</TI>
<SO>https://www.clinicaltrials.gov/ct2/show/NCT00467246</SO>
<YR>(last accessed 4 December 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-01-19 12:51:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-01-19 12:51:56 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00467246"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01365793" MODIFIED="2016-01-19 12:53:19 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01365793" YEAR="2015">
<REFERENCE MODIFIED="2016-01-19 12:53:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01365793</AU>
<TI>Randomized control trial of fluid therapy for pediatric diabetic ketoacidosis</TI>
<SO>https://www.clinicaltrials.gov/ct2/show/NCT01365793</SO>
<YR>(last accessed 4 December 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-16 17:51:02 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-16 17:51:02 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01365793"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02006342" MODIFIED="2016-01-19 12:54:13 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02006342" YEAR="2013">
<REFERENCE MODIFIED="2016-01-19 12:54:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02006342</AU>
<TI>Effectiveness of subcutaneous glargine on the time to closure of the anion gap in patients presenting to the emergency department with diabetic keto-acidosis (GT-COG)</TI>
<SO>https://www.clinicaltrials.gov/ct2/show/NCT02006342</SO>
<YR>(accessed 4 December 2015)</YR>
<IDENTIFIERS MODIFIED="2014-10-16 17:46:52 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-16 17:41:14 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-16 17:40:33 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT02006342"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Philotheou-2011" MODIFIED="2014-10-16 17:30:54 +0200" MODIFIED_BY="[Empty name]" NAME="Philotheou 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-10-16 17:30:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Philotheou A, Arslanian S, Blatniczky L, Peterkova V, Souhami E, Danne T</AU>
<TI>Comparable efficacy and safety of insulin glulisine and insulin lispro when given aspart of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type1 diabetes</TI>
<SO>Diabetes Technology &amp; Therapeutics</SO>
<YR>2011</YR>
<VL>3</VL>
<PG>327-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Savoldelli-2010" MODIFIED="2014-10-16 17:18:35 +0200" MODIFIED_BY="[Empty name]" NAME="Savoldelli 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-10-16 17:18:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Savoldelli RD, Farhat SC, Manna TD</AU>
<TI>Alternative management of diabetic ketoacidosis in a Brazilian pediatric emergency department</TI>
<SO>Diabetology &amp; Metabolic Syndrome</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Umpierrez-2009" MODIFIED="2014-10-16 17:31:01 +0200" MODIFIED_BY="[Empty name]" NAME="Umpierrez 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-10-16 17:31:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Umpierrez GE, Jones S, Smiley D, Mulligan P, Keyler T, Temponi A, et al</AU>
<TI>Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial</TI>
<SO>Diabetes Care</SO>
<YR>2009</YR>
<VL>7</VL>
<PG>1164-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vincent-2013" MODIFIED="2014-10-16 18:02:57 +0200" MODIFIED_BY="[Empty name]" NAME="Vincent 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-10-16 18:02:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vincent M, Nobécourt E</AU>
<TI>Treatment of diabetic ketoacidosis with subcutaneous insulin lispro: a review of the current evidence from clinical studies</TI>
<SO>Diabetes &amp; Metabolism</SO>
<YR>2013</YR>
<VL>39</VL>
<NO>4</NO>
<PG>299-305</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinzimer-2008" MODIFIED="2015-03-05 10:57:16 +0100" MODIFIED_BY="[Empty name]" NAME="Weinzimer 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-03-05 10:57:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM</AU>
<TI>A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>2</NO>
<PG>210-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yanai-2011" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Yanai 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yanai H, Adachi H, Hamasaki H</AU>
<TI>Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine</TI>
<SO>Diabetes Care</SO>
<YR>2011</YR>
<VL>34</VL>
<NO>6</NO>
<PG>e108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY DATA_SOURCE="MIX" ID="STD-El-Ebrashy-2010" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="El Ebrashy 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Ebrashy I, El Hefnawy MHMF, Basyouni A, Mahfouz H</AU>
<TI>Subcutaneous use of rapid insulin analog: an alternative treatment for patients with mild to moderate diabetic ketoacidosis</TI>
<SO>Pediatric Diabetes</SO>
<YR>2010</YR>
<VL>11(Suppl 14)</VL>
<PG>32 (O/6/FRI/01)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00920725" MODIFIED="2016-01-19 12:55:23 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00920725" YEAR="2009">
<REFERENCE MODIFIED="2016-01-19 12:55:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00920725</AU>
<TI>Subcutaneous aspart insulin to treat diabetic ketoacidosis (DKA) and beta-hydroxybutyrate testing in DKA</TI>
<SO>https://www.clinicaltrials.gov/ct2/show/NCT00920725</SO>
<YR>(last accessed 4 December 20015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2015-07-07 19:34:56 +0200" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<ADDITIONAL_REFERENCES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<REFERENCE ID="REF-ADA-1999" MODIFIED="2009-11-12 12:27:32 +0100" MODIFIED_BY="Bernd Richter" NAME="ADA 1999" TYPE="JOURNAL_ARTICLE">
<AU>The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</AU>
<TI>Report of the expert committee on the diagnosis and classification of diabetes mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>S5-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2004" MODIFIED="2014-02-24 01:57:35 +0100" MODIFIED_BY="[Empty name]" NAME="ADA 2004" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Hyperglycemic crises in diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>Suppl 1</NO>
<PG>S94-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2008" MODIFIED="2009-11-12 12:28:10 +0100" MODIFIED_BY="Bernd Richter" NAME="ADA 2008" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Standards of medical care in diabetes - 2008</TI>
<SO>Diabetes Care</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>Suppl 1</NO>
<PG>S12-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18165335"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alberti-1973" MODIFIED="2016-01-20 10:39:28 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Alberti 1973" TYPE="JOURNAL_ARTICLE">
<AU>Alberti KG, Hockaday TD, Turner RC</AU>
<TI>Small doses of intramuscular insulin in the treatment of diabetic "coma"</TI>
<SO>The Lancet</SO>
<YR>1973</YR>
<VL>2</VL>
<NO>7828</NO>
<PG>515-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2004" MODIFIED="2014-03-02 23:57:26 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, et al</AU>
<TI>Development and validation of the insulin treatment satisfaction questionnaire</TI>
<SO>Clinical Therapeutics</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>4</NO>
<PG>565-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Basu-1993" MODIFIED="2014-03-02 23:58:09 +0100" MODIFIED_BY="[Empty name]" NAME="Basu 1993" TYPE="JOURNAL_ARTICLE">
<AU>Basu A, Close CF, Jenkins D, Krentz AJ, Nattrass M, Wright AD</AU>
<TI>Persisting mortality in diabetic ketoacidosis</TI>
<SO>Diabetic Medicine</SO>
<YR>1993</YR>
<VL>10</VL>
<PG>282-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beller-2013" MODIFIED="2014-08-25 01:33:47 +0200" MODIFIED_BY="Megan J Prictor" NAME="Beller 2013" TYPE="JOURNAL_ARTICLE">
<AU>Beller EM, Chen JK, Wang UL, Glasziou PP</AU>
<TI>Are systematic reviews up-to-date at the time of publication?</TI>
<SO>Systematic Reviews</SO>
<YR>2013</YR>
<VL>2</VL>
<NO>1</NO>
<PG>36</PG>
<IDENTIFIERS MODIFIED="2014-08-25 01:33:47 +0200" MODIFIED_BY="Megan J Prictor"/>
</REFERENCE>
<REFERENCE ID="REF-Dave-2004" MODIFIED="2014-03-02 23:59:32 +0100" MODIFIED_BY="[Empty name]" NAME="Dave 2004" TYPE="JOURNAL_ARTICLE">
<AU>Dave J, Chatterjee S, Davies M, Higgins K, Morjaria H, McNally P, et al</AU>
<TI>Evaluation of admissions and management of diabetic ketoacidosis in a large teaching hospital</TI>
<SO>Practical Diabetes International</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>4</NO>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faich-1983" MODIFIED="2014-03-03 00:00:09 +0100" MODIFIED_BY="[Empty name]" NAME="Faich 1983" TYPE="JOURNAL_ARTICLE">
<AU>Faich GA, Fishbein HA, Ellis SE</AU>
<TI>The epidemiology of diabetic acidosis: a population-based study</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1983</YR>
<VL>117</VL>
<NO>5</NO>
<PG>551-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemkens-2009" MODIFIED="2014-02-21 17:28:42 +0100" MODIFIED_BY="[Empty name]" NAME="Hemkens 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al</AU>
<TI>Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study</TI>
<SO>Diabetologia</SO>
<YR>2009</YR>
<VL>52</VL>
<NO>9</NO>
<PG>1732-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2013-06-17 13:51:08 +0200" MODIFIED_BY="G P" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-06-17 13:28:07 +0200" MODIFIED_BY="G P" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2013-06-17 13:28:07 +0200" MODIFIED_BY="G P" NAME="Higgins 2009" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Spiegelhalter DJ</AU>
<TI>A re-evaluation of random-effects meta-analysis</TI>
<SO>Journal of the Royal Statistical Society: Series A (Statistics in Society)</SO>
<YR>2009</YR>
<VL>172</VL>
<NO>1</NO>
<PG>137-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2016-01-12 09:38:18 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2015-12-03 20:09:46 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al</AU>
<TI>The Cochrane Collaboration's tool for assessing risk of bias in randomized trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d5928</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Home-2000" MODIFIED="2014-03-03 00:02:03 +0100" MODIFIED_BY="[Empty name]" NAME="Home 2000" TYPE="JOURNAL_ARTICLE">
<AU>Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group</AU>
<TI>Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial</TI>
<SO>Diabetic Medicine</SO>
<YR>2000</YR>
<VL>17</VL>
<NO>11</NO>
<PG>762-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Home-2012" MODIFIED="2014-03-03 00:02:30 +0100" MODIFIED_BY="[Empty name]" NAME="Home 2012" TYPE="JOURNAL_ARTICLE">
<AU>Home PD</AU>
<TI>The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences</TI>
<SO>Diabetes, Obesity &amp; Metabolism</SO>
<YR>2012</YR>
<VL>14</VL>
<NO>9</NO>
<PG>780-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howey-1995" MODIFIED="2014-03-03 00:03:02 +0100" MODIFIED_BY="[Empty name]" NAME="Howey 1995" TYPE="JOURNAL_ARTICLE">
<AU>Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, et al</AU>
<TI>[Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>58</VL>
<NO>4</NO>
<PG>459-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hr_x00f3_bjartsson-2013" MODIFIED="2013-03-25 12:28:57 +0100" MODIFIED_BY="G P" NAME="Hróbjartsson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al</AU>
<TI>Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2013</YR>
<VL>185</VL>
<NO>4</NO>
<PG>E201-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1980" MODIFIED="2014-03-03 00:03:33 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 1980" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DD, Palumbo PJ, Chu CP</AU>
<TI>Diabetic ketoacidosis in a community-based population</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1980</YR>
<VL>55</VL>
<NO>2</NO>
<PG>83-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-2007" MODIFIED="2014-02-19 18:48:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kim S</AU>
<TI>Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States</TI>
<SO>Diabetes Care</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>5</NO>
<PG>1281-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirkham-2010" MODIFIED="2012-08-09 15:51:11 +0200" MODIFIED_BY="G P" NAME="Kirkham 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al</AU>
<TI>The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c365</PG>
<IDENTIFIERS MODIFIED="2012-02-03 16:22:08 +0100" MODIFIED_BY="Bernd Richter">
<IDENTIFIER MODIFIED="2012-02-03 16:22:08 +0100" MODIFIED_BY="Bernd Richter" TYPE="DOI" VALUE="10.1136/bmj.c365"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kitabchi-2001" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Kitabchi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al</AU>
<TI>Management of hyperglycemic crises in patients with diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<PG>131-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kitabchi-2009" MODIFIED="2014-02-19 18:56:06 +0100" MODIFIED_BY="[Empty name]" NAME="Kitabchi 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN</AU>
<TI>Hyperglycemic crises in adult patients with diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>7</NO>
<PG>1335-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurtzhals-2000" MODIFIED="2014-02-21 17:30:15 +0100" MODIFIED_BY="[Empty name]" NAME="Kurtzhals 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, et al</AU>
<TI>Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use</TI>
<SO>Diabetes</SO>
<YR>2000</YR>
<VL>49</VL>
<NO>6</NO>
<PG>999-1005</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2012-10-09 10:32:38 +0200" MODIFIED_BY="G P" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al</AU>
<TI>The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration</TI>
<SO>PLoS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>7</NO>
<PG>1-28</PG>
<IDENTIFIERS MODIFIED="2009-07-27 11:34:31 +0200" MODIFIED_BY="Bernd Richter">
<IDENTIFIER MODIFIED="2009-07-27 11:34:31 +0200" MODIFIED_BY="Bernd Richter" TYPE="DOI" VALUE="10.1371/journal.pmed.1000100"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Luzi-1988" MODIFIED="2014-02-20 17:50:23 +0100" MODIFIED_BY="[Empty name]" NAME="Luzi 1988" TYPE="JOURNAL_ARTICLE">
<AU>Luzi L, Barrett EJ, Groop LC, Ferrannini E, DeFronzo RA</AU>
<TI>Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis</TI>
<SO>Diabetes</SO>
<YR>1988</YR>
<VL>37</VL>
<NO>11</NO>
<PG>1470-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malone-1992" MODIFIED="2014-03-03 00:04:54 +0100" MODIFIED_BY="[Empty name]" NAME="Malone 1992" TYPE="JOURNAL_ARTICLE">
<AU>Malone ML, Gennis V, Goodwin JS</AU>
<TI>Characteristics of diabetic ketoacidosis in older versus younger adults</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1992</YR>
<VL>40</VL>
<NO>11</NO>
<PG>1100-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mathiesen-2007" MODIFIED="2014-02-21 17:35:04 +0100" MODIFIED_BY="[Empty name]" NAME="Mathiesen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, et al</AU>
<TI>Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women</TI>
<SO>Diabetes Care</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>4</NO>
<PG>771-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazer-2009" MODIFIED="2014-03-03 00:05:31 +0100" MODIFIED_BY="[Empty name]" NAME="Mazer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mazer M, Chen E</AU>
<TI>Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis?</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>2</NO>
<PG>259-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meader-2014" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Meader 2014" TYPE="JOURNAL_ARTICLE">
<AU>Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al</AU>
<TI>A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation</TI>
<SO>Systematic Reviews</SO>
<YR>2014</YR>
<VL>3</VL>
<PG>82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muir-2004" MODIFIED="2014-02-25 16:43:36 +0100" MODIFIED_BY="[Empty name]" NAME="Muir 2004" TYPE="JOURNAL_ARTICLE">
<AU>Muir AB, Quisling RG, Yang MC, Rosenbloom AL</AU>
<TI>Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>7</NO>
<PG>1541-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nyenwe-2011" MODIFIED="2014-03-03 00:06:12 +0100" MODIFIED_BY="[Empty name]" NAME="Nyenwe 2011" TYPE="JOURNAL_ARTICLE">
<AU>Nyenwe EA, Kitabchi AE</AU>
<TI>Evidence-based management of hyperglycemic emergencies in diabetes mellitus</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>2011</YR>
<VL>94</VL>
<NO>3</NO>
<PG>340-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rayman-2007" MODIFIED="2014-03-03 00:06:46 +0100" MODIFIED_BY="[Empty name]" NAME="Rayman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rayman G, Profozic V, Middle M</AU>
<TI>Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>2007</YR>
<VL>76</VL>
<NO>2</NO>
<PG>304-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riley-2011" MODIFIED="2012-04-19 18:18:56 +0200" MODIFIED_BY="Bernd Richter" NAME="Riley 2011" TYPE="JOURNAL_ARTICLE">
<AU>Riley RD, Higgins JP, Deeks JJ</AU>
<TI>Interpretation of random effects meta-analyses</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d549</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roach-2008" MODIFIED="2014-03-03 00:07:13 +0100" MODIFIED_BY="[Empty name]" NAME="Roach 2008" TYPE="JOURNAL_ARTICLE">
<AU>Roach P</AU>
<TI>New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations</TI>
<SO>Clinical Pharmacokinetics</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>9</NO>
<PG>595-610</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savage-2011" MODIFIED="2014-03-03 00:07:36 +0100" MODIFIED_BY="[Empty name]" NAME="Savage 2011" TYPE="JOURNAL_ARTICLE">
<AU>Savage MW, Dhatariya KK, Kilvert A, Rayman G, Rees JA, Courtney CH, et al</AU>
<TI>Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis</TI>
<SO>Diabetic Medicine</SO>
<YR>2011</YR>
<VL>28</VL>
<NO>5</NO>
<PG>508-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siebenhofer-2006" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Siebenhofer 2006" TYPE="COCHRANE_REVIEW">
<AU>Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al</AU>
<TI>Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-03-02 23:05:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-02 23:05:47 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003287"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2015-12-03 20:10:10 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warner-1998" MODIFIED="2014-03-03 00:09:58 +0100" MODIFIED_BY="[Empty name]" NAME="Warner 1998" TYPE="JOURNAL_ARTICLE">
<AU>Warner DP, Mckinney PA, Law GR, Bodansky HJ</AU>
<TI>Mortality and diabetes from a population based study in Yorkshire</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1998</YR>
<VL>78</VL>
<PG>435-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" MODIFIED="2009-07-27 12:53:59 +0200" MODIFIED_BY="Bernd Richter" NAME="WHO 1998" TYPE="JOURNAL_ARTICLE">
<AU>Alberti KM, Zimmet PZ</AU>
<TI>Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</TI>
<SO>Diabetic Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<PG>539-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2012-08-09 15:51:55 +0200" MODIFIED_BY="G P" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2012-04-19 17:53:46 +0200" MODIFIED_BY="Bernd Richter"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Study details" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Publication details" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Stated aim for study">
<INCLUDED_CHAR MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Della-Manna-2005">
<CHAR_METHODS MODIFIED="2015-12-03 20:57:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Parallel randomised controlled trial</B>
</P>
<P>
<B>Randomisation ratio:</B> 1:1</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria:</B> DKA, blood glucose &gt; 300 mg/dL, pH &lt; 7.3, and/or bicarbonate &lt; 15 mmol/L, and &gt; ++ ketonuria</P>
<P>
<B>Exclusion criteria</B>: surgery, use of glucocorticoid or immunosuppressive agents<BR/>
</P>
<P>
<B>Diagnostic criteria:</B> ADA criteria for DKA</P>
<P>
<B>Causes of DKA (n) - (subcutaneous insulin/intravenous insulin):</B>
</P>
<UL>
<LI>Excessive food intake: 13/13</LI>
<LI>Infection: 8/4</LI>
<LI>Missed injection: 10/5</LI>
<LI>New onset diabetes: 6/5</LI>
<LI>Unidentified: 1/4</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres:</B> 1</P>
<P>
<B>Treatment before study: </B>not stated</P>
<P>Group 1: s.c. insulin lispro. 0.15 IU/kg every 2 h until blood glucose &lt; 250 mg/dL, then every 4 h for the next 24 h (n = 30)</P>
<P>Group 2: i.v. regular insulin. 0.1 IU/kg/h, continuous infusion until blood glucose &lt; 250 mg/dL, and then 0.15 IU/kg subcutaneously every 4 h for 24 h (n = 30)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-04 07:21:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Composite outcome measures reported:</B> no</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-07-22 13:46:02 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Run-in period:</B> no</P>
<P>
<B>Study terminated before regular end (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-11-04 07:21:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Language of publication:</B> English</P>
<P>
<B>Non-commercial funding:</B> Fundacao de Amparo à Pesquisa do Estado de Sao Paulo grant (FAPESP 00/09682-7)</P>
<P>
<B>Publication status:</B> peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-11-04 07:21:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "... to compare the efficacy of a subcutaneous fast-acting analog (lispro) with continuous intravenous regular insulin (CIRI) in the treatment of pediatric DKA"</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-01-18 16:02:44 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Study authors randomised episodes of DKA, not participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Ers_x00f6_z-2006">
<CHAR_METHODS MODIFIED="2015-12-03 20:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Parallel randomised controlled trial</B>
</P>
<P>
<B>Randomisation ratio:</B> 1:1</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria: </B>DKA (mild or moderate only), serum blood glucose &gt; 250 mg/dL, arterial pH &lt; 7.3, bicarbonate &lt; 15 mmol/L, beta-hydroxybutyrate &gt; 1.6 mmol/L, ketonuria</P>
<P>
<B>Exclusion criteria: </B>plasma glucose &gt; 600 mg/dL, pH &lt; 7.0, bicarbonate &lt; 10 mmol/L, persistent hypotension, hypothermia, severe concomitant illness<BR/>
</P>
<P>
<B>Diagnostic criteria:</B> ADA criteria for DKA</P>
<P>
<B>Causes of DKA:</B> new onset diabetes (3 subcutaneous insulin lispro/2 intravenous regular insulin)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-18 16:02:05 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-04 07:21:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Composite outcome measures reported:</B> no</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-07-22 14:28:37 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Run-in period:</B> no</P>
<P>
<B>Study terminated before regular end (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-07-22 14:28:47 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication:</B> English</P>
<P>
<B>Commercial funding/non-commercial funding/other funding:</B> no</P>
<P>
<B>Publication status:</B> peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-11-04 07:21:38 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "... to evaluate the efficacy and safety of hourly SC insulin lispro administration in the treatment of DKA in comparison with standard IV regular insulin treatment"</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-11-04 07:21:38 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Karoli-2011">
<CHAR_METHODS MODIFIED="2015-12-03 20:58:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Parallel randomised controlled trial</B>
</P>
<P>
<B>Randomisation ratio:</B> 1:1</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria: </B>DKA (mild or moderate only, ADA criteria)</P>
<P>
<B>Exclusion criteria:</B> severe DKA and those requiring ICU admission, loss of consciousness, acute myocardial ischaemia, congestive heart failure, end-stage renal disease, anasarca, pregnancy, serious comorbidities, persistent hypotension<BR/>
</P>
<P>
<B>Diagnostic criteria:</B> ADA criteria for DKA</P>
<P>
<B>Causes of DKA</B> (% regular intravenous insulin/subcutaneous insulin lispro)</P>
<UL>
<LI>Infection: 56/52</LI>
<LI>Poor compliance: 32/40</LI>
<LI>New onset diabetes: 12/8</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-04 07:21:53 +0100" MODIFIED_BY="[Empty name]">
<P>Number of study centres: 1</P>
<P>Treatment before study: not stated</P>
<P>Titration period: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-04 07:21:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Composite outcome measures reported</B>: no</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-07-22 14:10:47 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Run-in period:</B> no</P>
<P>
<B>Study terminated before regular end (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-01-11 23:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Language of publication:</B> English</P>
<P>
<B>Commercial funding/non-commercial funding/other funding:</B> none</P>
<P>
<B>Publication status:</B> peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-11-04 07:21:58 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "... to compare the efficacy of insulin lispro subcutaneous 2 hourly in patients of mild to moderate DKA with standard intravenous regular insulin"</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-11-04 07:21:58 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Umpierrez--2004b">
<CHAR_METHODS MODIFIED="2015-12-03 20:59:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Parallel randomised controlled trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: "Uncomplicated DKA" defined by a plasma glucose level &gt; 250 mg/dL, serum bicarbonate level &lt; 15 mEq/L, venous pH &lt; 7.3, serum ketone level<BR/>at a dilution of greater than or equal to 1:4 by nitroprusside reaction, or serum beta-hydroxybutyrate level &gt; 3.0 mmol/L</P>
<P>
<B>Exclusion criteria:</B> persistent hypotension after the administration of 1 liter of normal saline (systolic blood pressure &lt; 80 mmHg), acute myocardial ischaemia, end-stage renal or hepatic failure, anasarca, dementia, or pregnancy</P>
<P>
<B>Diagnostic criteria: </B>ADA criteria for DKA</P>
<P>
<B>Causes of DKA (%): </B>poor compliance: 53 (s.c. insulin aspart, every hour)/60 (s.c. insulin aspart, every 2 hours)/60 (i.v. regular insulin); new onset diabetes: 20 (s.c. insulin aspart, every hour)/20 (s.c. insulin aspart, every 2 hours)/13 (i.v. regular insulin)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-03 21:22:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres: </B>1</P>
<P>
<B>Treatment before study:</B> not stated</P>
<P>
<B>Titration period:</B> no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-04 07:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Composite outcome measures reported:</B> no</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-07-22 14:17:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Run-in period:</B> no</P>
<P>
<B>Study terminated before regular end (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-01-12 00:12:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Language of publication:</B> English</P>
<P>
<B>Commercial funding:</B> unrestricted grant from Novo Nordisk; <B>non-commercial funding: </B>United States Public Health Services/National Institutes of Health grant (RR00211; General Clinical Research Center)</P>
<P>
<B>Publication status:</B> peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-11-04 07:22:48 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "We compared the efficacy and safety of aspart insulin given subcutaneously at different time intervals to a standard low-dose intravenous (IV) infusion protocol of regular insulin in patients with uncomplicated diabetic ketoacidosis (DKA)"</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-11-04 07:22:49 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Umpierrez-2004a">
<CHAR_METHODS MODIFIED="2015-12-03 20:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Parallel randomised controlled trial</B>
</P>
<P>
<B>Randomisation ratio: </B>1:1</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria:</B> plasma glucose level &gt; 250 mg/dL, serum bicarbonate level &lt; 15 mEq/L, venous pH &lt; 7.3, serum ketone level, beta-hydroxybutyrate &gt; 3 mmol/L</P>
<P>
<B>Exclusion criteria:</B> persistent hypotension after the administration of 1 liter of normal saline (systolic blood pressure &lt; 80 mmHg), acute myocardial ischaemia, heart failure, end-stage renal disease, anasarca, dementia, or pregnancy</P>
<P>
<B>Diagnostic criteria:</B> ADA criteria for DKA</P>
<P>
<B>Causes of DKA (%):</B> poor compliance: 60 (subcutaneous insulin lispro)/70 (intravenous regular insulin)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-03 21:22:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres:</B> 1</P>
<P>
<B>Treatment before study: </B>not stated</P>
<P>
<B>Titration period:</B> no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-04 07:23:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Composite outcome measures reported:</B> no</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-07-22 14:20:43 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Run-in period:</B> no</P>
<P>
<B>Study terminated before regular end (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication:</B> English</P>
<P>
<B>Commercial funding:</B> unrestricted grant from Eli Lilly; <B>non-commercial funding:</B> United States Public Health Services grant (RR00211)</P>
<P>
<B>Publication status:</B> peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-11-04 07:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To compare the efficacy and safety of subcutaneous insulin lispro with that of low-dose continuous intravenous regular insulin in the treatment of patients with uncomplicated diabetic ketoacidosis"</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-11-04 07:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Note: where the judgement is 'unclear risk' and the description is blank, the trial did not report that particular outcome</P>
<P>ADA: American Diabetes Association; DKA: diabetic ketoacidosis; ICU: intensive care unit; i.v.: intravenous; s.c.: subcutaneous<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-12-16 12:49:13 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Adesina-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-16 12:49:13 +0100" MODIFIED_BY="Bernd Richter">
<P>Intervention not relevant (insulin therapy was by the intramuscular route)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-14 15:43:51 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Armor-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-14 15:43:51 +0200" MODIFIED_BY="Bernd Richter">
<P>Not an RCT (case series)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Attia-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Not aimed at treating DKA (well-controlled insulin-dependent diabetes mellitus)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-16 12:49:40 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Fisher-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-16 12:49:40 +0100" MODIFIED_BY="Bernd Richter">
<P>Intervention not relevant (regular insulin by various routes)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-16 12:49:44 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Hsia-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-16 12:49:44 +0100" MODIFIED_BY="Bernd Richter">
<P>Intervention not relevant (s.c. administration of long-acting insulins)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-07 19:23:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kadowaki-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-07 19:23:56 +0200" MODIFIED_BY="[Empty name]">
<P>Not aimed at treating DKA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-16 12:50:06 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Liu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-16 12:50:06 +0100" MODIFIED_BY="Bernd Richter">
<P>Intervention not relevant (s.c. and i.v. infusion of regular insulin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-20 10:29:16 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-NCT00467246">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-20 10:29:16 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Intervention not relevant (insulin levemir)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-16 12:49:53 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-NCT01365793">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-16 12:49:53 +0100" MODIFIED_BY="Bernd Richter">
<P>Intervention not relevant (fluid therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-16 12:49:33 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-NCT02006342">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-16 12:49:33 +0100" MODIFIED_BY="Bernd Richter">
<P>Intervention not relevant (s.c. insulin glargine)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-07 19:23:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Philotheou-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-07 19:23:50 +0200" MODIFIED_BY="[Empty name]">
<P>Not aimed at treating DKA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-14 15:45:13 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Savoldelli-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-14 15:45:13 +0200" MODIFIED_BY="Bernd Richter">
<P>Not an RCT (review article)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-16 12:50:14 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Umpierrez-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-16 12:50:14 +0100" MODIFIED_BY="Bernd Richter">
<P>Intervention not relevant (i.v. regular or i.v. glulisine insulin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-14 15:45:41 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Vincent-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-14 15:45:41 +0200" MODIFIED_BY="Bernd Richter">
<P>Not an RCT (review article)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-07 19:23:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinzimer-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-07 19:23:35 +0200" MODIFIED_BY="[Empty name]">
<P>Not aimed at treating DKA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-14 15:45:51 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Yanai-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-14 15:45:51 +0200" MODIFIED_BY="Bernd Richter">
<P>Not an RCT (case report)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>DKA: diabetic ketoacidosis; i.v.: intravenous; RCT: randomised controlled trial: s.c.: subcutaneous</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Study details" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Publication details" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Stated aim of study">
<AWAITING_CHAR MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-El-Ebrashy-2010">
<CHAR_METHODS MODIFIED="2015-12-03 21:00:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-18 16:00:01 +0100" MODIFIED_BY="Gudrun Paletta">
<P>80 people with DKA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Group 1: regular insulin infusion (n = 20)</P>
<P>Group 2: s.c. rapid-acting insulin analogue aspart every 2 hours (n = 20)</P>
<P>Group 3: s.c. rapid-acting insulin analogue aspart every hour (n = 20)</P>
<P>Group 4: rapid-acting insulin analogue by subcutaneous insulin pump (n = 20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-15 20:07:33 +0200" MODIFIED_BY="[Empty name]">
<P>Time to resolution of DKA </P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-01-18 16:00:13 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Intervention model:</B> factorial design</P>
<P>
<B>Masking:</B> not stated</P>
<P>
<B>Primary purpose:</B> treatment</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-10-16 18:13:34 +0200" MODIFIED_BY="[Empty name]">
<P>Conference abstract</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>To look for technical simplification and economic efficiency in the treatment of DKA with s.c. use of rapid-acting insulin analogue and to compare its use with regular i.v. insulin treatment</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>No outcome data reported in abstract (authors contacted by email; no reply received)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-NCT00920725">
<CHAR_METHODS MODIFIED="2015-12-03 21:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Adults with DKA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Group 1: s.c. insulin aspart every 2 hours</P>
<P>Group 2: i.v. regular insulin</P>
<P>Group 3: i.v. insulin aspart (NovoLog)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-20 10:29:41 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Hours to resolution of ketoacidosis as defined as beta-hydroxybutyrate &lt; 0.6</P>
<P>Hours to achieve blood glucose less than 200 mg/dL</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-01-18 16:00:44 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Intervention model:</B> parallel assignment</P>
<P>
<B>Masking:</B> open label</P>
<P>
<B>Primary purpose:</B> treatment</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-01-12 00:41:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study start date:</B> January 2005</P>
<P>
<B>Study completion date:</B> December 2007</P>
<P>
<B>Primary completion date:</B> July 2007 (final data collection date for primary outcome measure)</P>
<P>Study not yet published (authors contacted by email; no reply received yet)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>To determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine whether it is useful to monitor beta-hydroxybutyrate during treatment of a diabetic crisis</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-01-18 15:59:54 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Responsible party:</B> David Baldwin, MD. Rush University Medical Center Chicago, Illinois, United States, 60612</P>
<P>Registered in ClinicalTrials.gov. Study completed, no results published</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>DKA: diabetic ketoacidosis; i.v.: intravenous; s.c.: subcutaneous</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-07-07 19:34:56 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Study identifier" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Official title" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Stated purpose of study">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-03 20:57:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Quote from publication: "Of the 60 DKA episodes, 30 were randomised to treatment with a subcutaneous fast-acting insulin analog (lispro) and the other 30 were randomised to treatment with CIRI"<BR/>
</P>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-04 07:21:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Quote from publication: "The patients were randomly assigned into two groups"</P>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-03 20:58:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Quote from publication: "The study patients were randomised in emergency department following a computer generated randomisation table in two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Quote from publication: "Patients were randomly assigned in the emergency department to receive SC aspart insulin every hour (SC-1h, n15) or every 2 h (SC-2h, n15), or to receive IV regular insulin (n15)"</P>
<P>Comment: insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-03 20:59:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Quote from publication: "Patients were assigned in the emergency department to receive subcutaneous insulin lispro or intravenous regular insulin following a computer-generated randomisation table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-11-04 07:22:50 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-04 07:21:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-04 07:21:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-04 07:22:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-04 07:22:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 11:13:16 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.05" NO="5">
<NAME>Non-hypoglycaemic adverse events</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.07" NO="7">
<NAME>HbA1c</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.04" NO="4">
<NAME>Morbidity</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.08" NO="8" REF_IDS="CMP-001.04 CMP-002.04">
<NAME>Socioeconomic effects</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1" REF_IDS="CMP-001.01 CMP-001.01 CMP-002.01">
<NAME>Time to resolution of diabetic ketoacidosis</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2" REF_IDS="CMP-001.02 CMP-002.02">
<NAME>All-cause mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.03" NO="3" REF_IDS="CMP-001.03 CMP-002.03">
<NAME>Hypoglycaemic episodes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.06" NO="6">
<NAME>Patient satisfaction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-11-04 07:21:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: participants and personnel were probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-11-04 07:21:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: study personnel/participants probably not blinded, but outcome measurement unlikely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2016-01-20 10:27:09 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: study personnel/participants probably not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2015-11-04 07:21:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: study personnel/participants probably not blinded, but outcome measurement unlikely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-12-15 18:34:52 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2015-12-15 18:34:52 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2015-12-15 18:34:52 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.08" MODIFIED="2015-12-15 18:34:52 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-11-04 07:21:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: participants and personnel were probably not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-11-04 07:21:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: study personnel/participants probably not blinded, but outcome measurement unlikely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2015-11-04 07:21:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: study personnel/participants probably not blinded, outcome measurement not defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2015-10-16 18:10:33 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-10-16 18:10:34 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2015-10-16 18:10:34 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2015-10-16 18:10:34 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.08" MODIFIED="2015-10-16 18:10:34 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Quote from publication: "In this prospective, randomised and open trial ..."</P>
<P>Comment: participants and personnel were unblinded (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Quote from publication: "In this prospective, randomised and open trial ..."</P>
<P>Comment: participants and study personnel not blinded, but outcome measurement not likely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Quote from publication: "In this prospective, randomised and open trial ..."</P>
<P>Comment: participants and personnel were unblinded (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Quote from publication: "In this prospective, randomised and open trial ..."</P>
<P>Comment: participants and personnel were unblinded (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.08" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Quote from publication: "In this prospective, randomised and open trial ..."</P>
<P>Comment: participants and personnel were unblinded (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-03 20:59:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Quote from publication: "In this prospective, randomised, open trial ..."</P>
<P>Comment: participants and personnel were unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-12-03 20:59:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Quote from publication: "In this prospective, randomised, open trial ..."</P>
<P>Comment: outcome measurement not likely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2015-12-03 20:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Quote from publication: "In this prospective, randomised, open trial ..."</P>
<P>Comment: unclear whether outcome was influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.08" MODIFIED="2015-12-03 20:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Quote from publication: "In this prospective, randomised, open trial ..."</P>
<P>Comment: unclear whether outcome was influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-22 14:22:06 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Quote from publication: "open trial"</P>
<P>Comment: participants and personnel were unblinded (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-01-12 00:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: study personnel not blinded, but outcome measurement not likely to be influenced by the lack of blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2015-11-04 07:23:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: unclear whether outcome was influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.08" MODIFIED="2015-11-04 07:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Quote from publication: "open trial"</P>
<P>Comment: participants and personnel were unblinded (open trial)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-12-15 18:35:00 +0100" MODIFIED_BY="Bernd Richter" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.06" NO="6">
<NAME>Patient satisfaction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2" REF_IDS="CMP-001.02 CMP-002.02">
<NAME>All-cause mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.07" NO="7">
<NAME>HbA1c</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.05" NO="5">
<NAME>Non-hypoglycaemic adverse events</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.08" NO="8" REF_IDS="CMP-001.04 CMP-002.04">
<NAME>Socioeconomic effects</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.03" NO="3">
<NAME>Morbidity</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.04" NO="4" REF_IDS="CMP-001.03 CMP-002.03">
<NAME>Hypoglycaemic episodes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.01 CMP-001.01 CMP-002.01">
<NAME>Time to resolution of diabetic ketoacidosis</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-04 07:21:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-12-15 18:35:00 +0100" MODIFIED_BY="Bernd Richter" RESULT="YES" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: no detailed information, but outcome measurement unlikely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-11-04 07:21:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: no detailed information, but outcome measurement unlikely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-11-04 07:21:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-12-15 18:34:53 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2015-12-15 18:34:53 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2015-12-15 18:34:53 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.08" MODIFIED="2015-12-15 18:34:53 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-04 07:21:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-11-04 07:21:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: no detailed information, but outcome measurement unlikely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-10-16 18:10:33 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-11-04 07:21:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: no detailed information, but outcome measurement unlikely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-10-16 18:10:33 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2015-10-16 18:10:33 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2015-10-16 18:10:33 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.08" MODIFIED="2015-10-16 18:10:33 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-04 07:22:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-11-04 07:22:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: no detailed information, outcome not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-11-04 07:22:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-11-04 07:22:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.08" MODIFIED="2015-11-04 07:22:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-04 07:22:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-11-04 07:22:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: outcome measurement not likely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-11-04 07:22:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.08" MODIFIED="2015-11-04 07:22:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-04 07:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-11-04 07:41:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P> Comment: no information on blinding of outcome assessment, but outcome measurement not likely to be influenced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-11-04 07:41:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.08" MODIFIED="2015-11-04 07:41:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: no detailed information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-01-18 16:02:30 +0100" MODIFIED_BY="Gudrun Paletta" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.07" NO="7">
<NAME>HbA1c</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.08" NO="8" REF_IDS="CMP-001.04 CMP-002.04">
<NAME>Socioeconomic effects</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2" REF_IDS="CMP-001.02 CMP-002.02">
<NAME>All-cause mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.05" NO="5">
<NAME>Non-hypoglycaemic adverse events</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.04" NO="4">
<NAME>Morbidity</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3" REF_IDS="CMP-001.03 CMP-002.03">
<NAME>Hypoglycaemic episodes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.06" NO="6">
<NAME>Patient satisfaction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01 CMP-002.01 CMP-001.01">
<NAME>Time to resolution of diabetic ketoacidosis</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-04 07:21:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: reasons for dropouts explained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-01-18 16:02:30 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: DKA occurrences randomised, not participants (unclear which participants had only 1 DKA)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2016-01-18 16:02:26 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>
<BR/>Comment: DKA occurrences randomised, not participants (unclear which participants had only 1 DKA)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-01-18 16:02:20 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: DKA occurrences randomised, not participants (unclear which participants had only 1 DKA)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-12-15 18:34:53 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2015-12-15 18:34:53 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2015-12-15 18:34:53 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.08" MODIFIED="2015-12-15 18:34:53 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-03 20:57:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-12-03 20:58:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2015-12-03 20:58:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2015-10-16 18:10:33 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-10-16 18:10:33 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2015-10-16 18:10:34 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2015-10-16 18:10:32 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.08" MODIFIED="2015-10-16 18:10:34 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-03 20:58:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-12-03 20:58:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2015-12-03 20:58:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2015-12-03 20:58:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" RESULT="UNKNOWN" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.08" MODIFIED="2015-12-03 20:58:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-03 20:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-12-03 20:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2015-12-03 20:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2015-10-15 17:31:35 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2015-10-15 17:27:40 +0200" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.08" MODIFIED="2015-12-03 20:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-03 20:59:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-12-03 20:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2015-12-03 20:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.08" MODIFIED="2015-12-03 20:59:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: all randomised participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-01-18 16:02:12 +0100" MODIFIED_BY="Gudrun Paletta" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-18 16:02:12 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: possible outcome reporting bias for time to resolution of DKA (see <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-18 16:01:54 +0100" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: possible outcome reporting bias for time to resolution of DKA (see <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-04 07:22:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-04 07:22:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-04 07:41:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-12-15 18:35:15 +0100" MODIFIED_BY="Bernd Richter" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-21 17:32:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Della-Manna-2005">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-21 17:26:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ers_x00f6_z-2006">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-21 17:18:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karoli-2011">
<DESCRIPTION>
<P>Comment: none detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-15 18:35:15 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez--2004b">
<DESCRIPTION>
<P>Comment: possible sponsor bias (unrestrictive grant from Novo Nordisk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-04 07:41:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Umpierrez-2004a">
<DESCRIPTION>
<P>Comment: possible sponsor bias (unrestrictive grant from Eli Lilly)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2014-09-14 22:48:13 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-09-14 21:58:21 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-10-20 18:19:53 +0200" MODIFIED_BY="Bernd Richter">Subcutaneous insulin lispro versus intravenous regular insulin for diabetic ketoacidosis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>Subcutaneous insulin lispro versus intravenous regular insulin for diabetic ketoacidosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>Patient:</B> participants with diabetic ketoacidosis<BR/>
<B>Settings: </B>emergency department and critical care unit<BR/>
<B>Intervention:</B> subcutaneous insulin lispro versus intravenous regular insulin<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Intravenous regular insulin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Subcutaneous insulin lispro</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>All-cause mortality (N)</B>
</P>
<P>Mean hospital stay: 2-7 days</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>156 (4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>a</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No deaths reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hypoglycaemic episodes (N)</B>
</P>
<P>Mean hospital stay: 2-7 days</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>70 per 1000</B>
<BR/>(27 to 180)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.59 </B>
<BR/>(0.23 to 1.52)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>156 (4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>b</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Comparable risk ratios for adults (4 trials) and children (1 trial)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Morbidity (N)</B>
</P>
<P>Mean hospital stay: 2-7 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>96 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No cases of cerebral oedema, venous thrombosis, adult respiratory distress syndrome, hyperchloraemic acidosis</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events other than hypoglycaemic episodes</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Time to resolution of diabetic ketoacidosis (h)</B>
</P>
<P>Mean hospital stay: 2-4 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean time to resolution of diabetic ketoacidosis across the intravenous regular insulin groups was 11 h<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean time to resolution of diabetic ketoacidosis in the subcutaneous insulin lispro groups was <B>0.2 h higher </B>(1.7 h lower to 2.1 h higher)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>90 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low<SUP>c</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Metabolic acidosis and ketosis took longer to resolve in the subcutaneous insulin lispro group in 1 trial (60 children); no exact data published</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Patient satisfaction</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Socioeconomic effects: length of hospital stay (days)</B>
</P>
<P>Mean hospital stay: 4-7 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean length of hospital stay in the intravenous regular insulin groups ranged between 4 and 6.6 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean length of hospital stay in the subcutaneous insulin lispro groups was <B>0.4 days shorter</B> (1 day shorter to 0.2 days longer)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>90 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>d</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>US setting: treatment of diabetic ketoacidosis in a non&#8211;intensive care setting (step-down unit or general medicine ward) was associated with a 39% lower hospitalisation charge than was treatment with intravenous regular insulin in the intensive care unit (USD 8801 (SD USD 5549) vs USD 14,429 (SD USD 5243); the average hospitalisation charges per day were USD 3981 (SD USD 1067) for participants treated in an intensive care unit compared with USD 2682 (SD USD 636) for those treated in a non&#8211;intensive care setting</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>h: </B>hours; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Assumed risk was derived from the event rates in the comparator groups.<BR/>
<SUP>a</SUP>Downgraded by one level because of imprecision (see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>).<BR/>
<SUP>b</SUP>Downgraded by two levels because of risk of performance bias and serious imprecision (see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>).<BR/>
<SUP>c</SUP>Downgraded by three levels because of risk of performance bias, serious risk of inconsistency, and serious risk of imprecision (see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>).<BR/>
<SUP>d</SUP>Downgraded by two levels because of serious risk of imprecision (see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-10-20 18:21:26 +0200" MODIFIED_BY="Bernd Richter">Subcutaneous insulin aspart versus intravenous regular insulin for diabetic ketoacidosis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>Subcutaneous insulin aspart versus intravenous regular insulin for diabetic ketoacidosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>Patient:</B> participants with diabetic ketoacidosis<BR/>
<B>Settings: </B>general medicine ward and intensive care unit<BR/>
<B>Intervention:</B> subcutaneous insulin aspart versus intravenous regular insulin<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Intravenous regular insulin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Subcutaneous insulin aspart</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>All-cause mortality (N)</B>
</P>
<P>Mean hospital stay: 3-5 days</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>45 (1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>a</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No deaths reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hypoglycaemic episodes (N)</B>
</P>
<P>Mean hospital stay: 3-5 days</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
<BR/>(5 to 970)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 1.00 </B>
<BR/>(0.07 to 14.55)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>b</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Morbidity</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events other than hypoglycaemic episodes</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Time to resolution of diabetic ketoacidosis (h)</B>
</P>
<P>Mean hospital stay: 3-5 days</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean time to resolution of diabetic ketoacidosis across the intravenous regular insulin groups was 11 h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean time to resolution of diabetic ketoacidosis in the subcutaneous insulin aspart group was <B>1 h lower </B>(3.2 h lower to 1.2 h higher)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low<SUP>c</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Patient satisfaction</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Socioeconomic effects: length of hospital stay (days)</B>
</P>
<P>Mean hospital stay: 3-5 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean length of hospital stay in the intravenous regular insulin group was 4.5 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean length of hospital stay in the subcutaneous insulin aspart group was <B>1.1 days shorter</B> (3.3 days shorter to 1.1 days longer)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>d</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>h: </B>hours; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Assumed risk was derived from the event rates in the comparator groups<BR/>
<SUP>a</SUP>Downgraded by two levels because of serious imprecision (see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>)<BR/>
<SUP>b</SUP>Downgraded by two levels because of risk of performance bias and imprecision (see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>)<BR/>
<SUP>c</SUP>Downgraded by three levels because of risk of performance bias and serious risk of imprecision (see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>)<BR/>
<SUP>d</SUP>Downgraded by two levels because of serious risk of imprecision (see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>)</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="1">
<TITLE MODIFIED="2014-09-14 22:07:08 +0200" MODIFIED_BY="[Empty name]">Overview of study populations</TITLE>
<TABLE COLS="9" ROWS="20">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Sample size<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Screened/eligible<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Randomised<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Analysed<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Finishing trial<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Randomised finishing trial<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Follow-up time<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Arbitrary estimation of a difference between groups of &#8805; 5 hours to determine ketoacidosis as being clinically important; a sample size of 20 participants was needed in each group to provide a power of 0.93, given an alpha level of 0.05, a SD of 4, and a 1:1 inclusion ratio</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
<P/>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Mean hospital stay: 4 days</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="4" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD VALIGN="TOP">
<P>I1: s.c. insulin aspart, every hour</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Arbitrary estimation of a difference between groups of &#8805; 4 hours to determine ketoacidosis as being clinically significant. A sample size of 15 participants was needed in each group to provide a power of 0.81, given an alpha error of 0.05 and a SD of 3</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>Mean hospital stay: 3.4 days</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: s.c. insulin aspart, every 2 h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>Mean hospital stay: 3.9 days</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>Mean hospital stay: 4.5 days</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Mean hospital stay: 2-3 days</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="RIGHT" COLSPAN="2" VALIGN="TOP">
<P>total:</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<B>Karoli 2011</B>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean hospital stay: 6 days</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean hospital stay: 6.6 days</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="RIGHT" VALIGN="TOP">
<P>
<B>total:</B>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<I>Grand total</I>
<BR/>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>
<I>All interventions</I>
</B>
</P>
</TH>
<TD COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P/>
</TD>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>110</I>
</P>
</TH>
<TD ROWSPAN="3" VALIGN="TOP">
<P/>
</TD>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>110</I>
<BR/>
</P>
</TH>
<TD COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>
<I>All c</I>
</B>
<I>omparator<B>s</B>
</I>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>91</I>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>91</I>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<B>
<I>All interventions and c</I>
</B>
<I>omparator<B>s</B>
</I>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>201</I>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<I>201</I>
</P>
</TH>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>According to power calculation in study publication or report<BR/>
<SUP>b</SUP>Duration of intervention and/or follow-up under randomised conditions until end of study</P>
<P>- denotes not reported</P>
<P>C: comparator; I: intervention; i.v.: intravenous; s.c.: subcutaneous; SD: standard deviation</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<COMPARISON ID="CMP-001" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="1">
<NAME>Insulin lispro versus regular insulin</NAME>
<CONT_OUTCOME CHI2="3.3843823919024985" CI_END="0.9016010997873474" CI_START="-0.6440162531413796" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.12879242332298393" ESTIMABLE="YES" I2="70.45251144218784" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.06581692109639614" P_Q="1.0" P_Z="0.7439418650118306" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.21925358985677823" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" UNITS="h" WEIGHT="100.0" Z="0.32663778097000346">
<NAME>Time to resolution of diabetic ketoacidosis</NAME>
<GROUP_LABEL_1>Insulin lispro</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular insulin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin lispro</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regular insulin</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0758336517540454" CI_START="-0.0524143214599424" EFFECT_SIZE="0.5117096651470515" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="11.0" MODIFIED="2014-11-03 23:41:43 +0100" MODIFIED_BY="[Empty name]" ORDER="2" SD_1="2.2" SD_2="1.6" SE="0.2878236493408715" STUDY_ID="STD-Karoli-2011" TOTAL_1="25" TOTAL_2="25" WEIGHT="51.46390775549734"/>
<CONT_DATA CI_END="0.34586530128115806" CI_START="-0.9003119429532589" EFFECT_SIZE="-0.27722332083605045" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="11.0" MODIFIED="2014-11-03 23:43:26 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="3.0" SD_2="4.0" SE="0.3179081998608403" STUDY_ID="STD-Umpierrez-2004a" TOTAL_1="20" TOTAL_2="20" WEIGHT="48.536092244502655"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="80" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Insulin lispro</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular insulin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin lispro</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regular insulin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-03 23:45:50 +0100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.0" STUDY_ID="STD-Umpierrez-2004a" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-16 13:24:47 +0200" MODIFIED_BY="Bernd Richter" ORDER="17" O_E="0.0" SE="0.0" STUDY_ID="STD-Della-Manna-2005" TOTAL_1="25" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-03 23:45:52 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.0" STUDY_ID="STD-Ers_x00f6_z-2006" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-03 23:45:54 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-Karoli-2011" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17422072100962324" CI_END="1.5242451384558757" CI_START="0.22864782455157692" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.590351873877989" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.18305481852410116" LOG_CI_START="-0.6408329263180262" LOG_EFFECT_SIZE="-0.2288890538969626" METHOD="MH" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="3" P_CHI2="0.9165759751435862" P_Q="0.8639118621917288" P_Z="0.2761459542193492" Q="0.029376837428452166" RANDOM="YES" SCALE="782.47" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="76" WEIGHT="100.0" Z="1.0890180243655814">
<NAME>Hypoglycaemic episodes</NAME>
<GROUP_LABEL_1>Insulin lispro</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular insulin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin lispro</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regular insulin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.144809720781165" CI_END="3.936022800209546" CI_START="0.11491851089930288" DF="1" EFFECT_SIZE="0.6725487930743652" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.595057605505369" LOG_CI_START="-0.9396100101810101" LOG_EFFECT_SIZE="-0.17227620233782057" MODIFIED="2014-11-08 01:09:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7035456899531083" P_Z="0.6599104192230519" STUDIES="3" TAU2="0.0" TOTAL_1="55" TOTAL_2="55" WEIGHT="28.82089267228816" Z="0.44003685035661266">
<NAME>Adults</NAME>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-03 23:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Umpierrez-2004a" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="12.32700831164132"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-03 23:52:04 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.0" STUDY_ID="STD-Ers_x00f6_z-2006" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.167657331603573" CI_START="0.04837782073340814" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7132937077873972" LOG_CI_START="-1.3153536991153596" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-11-03 23:52:17 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Karoli-2011" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="16.493884360646838"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7236932467916635" CI_START="0.1819349240844962" DF="0" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.23645998012025313" LOG_CI_START="-0.7400839261078521" LOG_EFFECT_SIZE="-0.25181197299379954" MODIFIED="2015-10-21 15:25:20 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="1.0" P_Z="0.3121150125891866" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="21" WEIGHT="71.17910732771183" Z="1.0107940765308225">
<NAME>Children</NAME>
<DICH_DATA CI_END="1.7236932467916635" CI_START="0.1819349240844962" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.23645998012025313" LOG_CI_START="-0.7400839261078521" LOG_EFFECT_SIZE="-0.25181197299379954" MODIFIED="2015-10-21 15:25:20 +0200" MODIFIED_BY="Bernd Richter" ORDER="18" O_E="0.0" SE="0.5736267244886861" STUDY_ID="STD-Della-Manna-2005" TOTAL_1="25" TOTAL_2="21" VAR="0.32904761904761903" WEIGHT="71.17910732771183"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.9054325955734397" CI_END="0.21982406547588285" CI_START="-0.9743512284537496" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.37726358148893335" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="4" P_CHI2="0.3413293224777997" P_Q="1.0" P_Z="0.2155742035167464" Q="0.0" RANDOM="YES" SCALE="5.41" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" UNITS="days" WEIGHT="99.99999999999999" Z="1.2383827335159594">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Insulin lispro</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular insulin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin lispro</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regular insulin</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9799819922700271" CI_START="-0.9799819922700271" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.0" MODIFIED="2015-10-15 12:01:24 +0200" MODIFIED_BY="Bernd Richter" ORDER="17" SD_1="2.0" SD_2="1.0" SE="0.5" STUDY_ID="STD-Umpierrez-2004a" TOTAL_1="20" TOTAL_2="20" WEIGHT="37.12273641851106"/>
<CONT_DATA CI_END="0.15299357363423338" CI_START="-1.3529935736342327" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.6" MODIFIED="2014-11-03 23:55:55 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="1.2" SD_2="1.5" SE="0.38418745424597095" STUDY_ID="STD-Karoli-2011" TOTAL_1="25" TOTAL_2="25" WEIGHT="62.877263581488926"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="2">
<NAME>Insulin aspart versus regular insulin</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.25" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="h" WEIGHT="0.0" Z="0.0">
<NAME>Time to resolution of diabetic ketoacidosis</NAME>
<GROUP_LABEL_1>Insulin aspart</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular insulin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin aspart</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regular insulin</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1470329724605888" CI_START="-3.1470329724605888" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="11.0" MODIFIED="2014-11-08 00:57:37 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="3.0" SD_2="3.0" SE="1.0954451150103321" STUDY_ID="STD-Umpierrez--2004b" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Insulin aspart</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular insulin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin aspart</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regular insulin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-08 00:56:47 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.0" STUDY_ID="STD-Umpierrez--2004b" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="126.94" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Hypoglycaemic episodes</NAME>
<GROUP_LABEL_1>Insulin aspart</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular insulin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin aspart</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regular insulin</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-08 00:56:07 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Umpierrez--2004b" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.87" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="days" WEIGHT="0.0" Z="0.0">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Insulin aspart</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular insulin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin aspart</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regular insulin</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0470329724605887" CI_START="-3.247032972460589" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="4.5" MODIFIED="2014-11-08 00:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="3.0" SD_2="3.0" SE="1.0954451150103321" STUDY_ID="STD-Umpierrez--2004b" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-01-20 10:39:34 +0100" MODIFIED_BY="Gudrun Paletta">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA70AAAPcCAYAAACNddxTAACAAElEQVR42uzdD+RW5+M//g9JJknM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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-01-20 10:39:34 +0100" MODIFIED_BY="Gudrun Paletta" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0sAAAMNCAMAAAB+mx81AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-01-20 10:39:34 +0100" MODIFIED_BY="Gudrun Paletta" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the trial did not measure that particular outcome).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8UAAALYCAIAAADab8fKAABNpElEQVR42u3dz24cRduG8ZGQEItZ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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-01-20 10:44:15 +0100" MODIFIED_BY="Gudrun Paletta">
<APPENDIX ID="APP-01" MODIFIED="2015-12-15 17:13:59 +0100" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2009-11-05 15:50:00 +0100" MODIFIED_BY="Bernd Richter">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-12-15 17:13:59 +0100" MODIFIED_BY="Bernd Richter">
<TABLE COLS="1" ROWS="16">
<TR>
<TH>
<P>
<B>Cochrane Library</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1. [mh "Diabetic Ketoacidosis"]<BR/>2. [mh "Diabetic Coma"]<BR/>3. (("hyperglycaemic" or "hyperglycemic" or diabet*) next emergenc*):ti,ab,kw<BR/>4. (diabet* and (keto* or acidos* or "coma")):ti,ab,kw<BR/>5. "DKA":ti,ab,kw<BR/>6. {or #1-#5}<BR/>7. [mh "Insulin Lispro"]<BR/>8. [mh "Insulin Aspart"]<BR/>9. [mh "Insulin, Short-Acting"]<BR/>10. ("glulisine" or "apidra"):ti,ab,kw<BR/>11. ("humulin" or "novolin"):ti,ab,kw<BR/>12. ("lispro" or "aspart"):ti,ab,kw<BR/>13. ("novolog" or "novorapid"):ti,ab,kw<BR/>14. (insulin* near/4 analogue*):ti,ab,kw<BR/>15. (acting next insulin*):ti,ab,kw<BR/>16. {or #7-#15}<BR/>17. #6 and #16</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>MEDLINE (Ovid SP)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1. Diabetic Ketoacidosis/<BR/>2. Diabetic Coma/<BR/>3. ((hyperglyc?emic or diabet*) adj emergenc*).tw.<BR/>4. (diabet* and (keto* or acidos* or coma)).tw.<BR/>5. DKA.tw.<BR/>6. or/1-5<BR/>7. Insulin Lispro/<BR/>8. Insulin Aspart/<BR/>9. Insulin, Short-Acting/<BR/>10. (glulisine or apidra).tw.<BR/>11. (humulin or novolin).tw.<BR/>12. (lispro or aspart).tw.<BR/>13. (novolog or novorapid).tw.<BR/>14. (insulin* adj3 analogue*).tw.<BR/>15. acting insulin*.tw.<BR/>16. or/7-15<BR/>17. 6 and 16<BR/>18. exp animals/ not humans/<BR/>19. 17 not 18</P>
</TD>
</TR>
<TR>
<TH>
<P>PubMed</P>
</TH>
</TR>
<TR>
<TD>
<P>#1 (hyperglycemic emergenc*[tw] OR hyperglycaemic emergenc*[tw] OR diabetic emergenc*[tw] OR (diabet*[tw] AND (ketoac*[tw] OR acidos*[tw] OR coma[tw])) OR DKA[tw])</P>
<P>#2 (glulisine[tw] OR apidra[tw] OR humulin[tw] OR novolin[tw] OR lispro[tw] OR aspart[tw] OR novolog[tw] OR novorapid[tw] OR (insulin[tw] AND analog*[tw]) OR acting insulin*[tw])</P>
<P>#3 #1 AND #2</P>
<P>#4 #3 NOT medline[sb] NOT pmcbook</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>EMBASE (Ovid SP)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1. diabetic ketoacidosis/<BR/>2. diabetic coma/<BR/>3. ((hyperglyc?emic or diabet*) adj emergenc*).tw.<BR/>4. (diabet* and (keto* or acidos* or coma)).tw.<BR/>5. DKA.tw.<BR/>6. or/1-5<BR/>7. insulin lispro/<BR/>8. insulin aspart/<BR/>9. insulin glulisine/<BR/>10. short acting insulin/<BR/>11. (glulisine or apidra).tw.<BR/>12. (humulin or novolin).tw.<BR/>13. (lispro or aspart).tw.<BR/>14. (novolog or novorapid).tw.<BR/>15. (insulin* adj3 analogue*).tw.<BR/>16. acting insulin*.tw.<BR/>17. or/7-16<BR/>18. 6 and 17<BR/>
<I>[19: Wong et al. 2006 "sound treatment studies" filter &#8211; BS version] </I>
<BR/>19. random*.tw. or clinical trial*.mp. or exp health care quality/<BR/>20. 18 and 19<BR/>21. limit 20 to embase</P>
</TD>
</TR>
<TR>
<TH>
<P>LILACS (IAHx)</P>
</TH>
</TR>
<TR>
<TD>
<P>(MH: "Diabetic Ketoacidosis" OR MH: "Diabetic Coma" OR (diabet$ AND (keto$ OR acidos$ OR "coma"))) AND (MH: "Insulin Lispro" OR MH: "Insulin Aspart" OR MH: "Insulin, Short-Acting" OR ("glulisine" OR "apidra") OR ("humulin" OR "novolin") OR ("lispro" OR "aspart") OR ("novolog" OR "novorapid") OR (insulin$ AND analogue$) OR (acting AND insulin$))<BR/>+ Filter "Controlled Clinical Trial"</P>
</TD>
</TR>
<TR>
<TH>
<P>CINAHL (Ebsco)</P>
</TH>
</TR>
<TR>
<TD>
<P>S1. MH "Diabetic Ketoacidosis"<BR/>S2. MH "Diabetic Coma"<BR/>S3. TI (("hyperglycaemic" OR "hyperglycemic" OR diabet*) N1 emergenc*) OR AB (("hyperglycaemic" OR "hyperglycemic" OR diabet*) N1 emergenc*)<BR/>S4. TI (diabet* AND (keto* OR acidos* OR "coma")) OR AB (diabet* AND (keto* OR acidos* OR "coma"))<BR/>S5. TI ("DKA") OR AB ("DKA")<BR/>S6. S1 OR S2 OR S3 OR S4 OR S5<BR/>S7. MH "Insulin Lispro"<BR/>S8. MH "Insulin Aspart"<BR/>S9. MH "Insulin, Short-Acting"<BR/>S10. TI ("glulisine" OR "apidra") OR AB ("glulisine" OR "apidra")<BR/>S11. TI ("humulin" OR "novolin") OR AB ("humulin" OR "novolin")<BR/>S12. TI ("lispro" OR "aspart") OR AB ("lispro" OR "aspart")<BR/>S13. TI ("novolog" OR "novorapid") OR AB ("novolog" OR "novorapid")<BR/>S14. TI (insulin* N3 analogue*) OR AB (insulin* N3 analogue*)<BR/>S15. TI (acting N1 insulin*) OR AB (acting N1 insulin*)<BR/>S16. S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15<BR/>S17. S6 AND S16</P>
</TD>
</TR>
<TR>
<TH>
<P>ICTRP Search Portal</P>
</TH>
</TR>
<TR>
<TD>
<P>
<I>Standard search:</I>
<BR/>diabet* AND keto* AND lispro OR<BR/>diabet* AND acidos* AND lispro OR<BR/>diabet* AND coma AND lispro OR<BR/>diabet* AND keto* AND aspart OR<BR/>diabet* AND acidos* AND aspart OR<BR/>diabet* AND coma AND aspart OR<BR/>diabet* AND keto* AND acting insulin OR<BR/>diabet* AND acidos* AND acting insulin OR<BR/>diabet* AND coma AND acting insulin OR<BR/>diabet* AND keto* AND analogue* OR<BR/>diabet* AND acidos* AND analogue* OR<BR/>diabet* AND coma AND analogue* OR<BR/>diabet* AND keto* AND glulisine OR<BR/>diabet* AND acidos* AND glulisine OR<BR/>diabet* AND coma AND glulisine</P>
</TD>
</TR>
<TR>
<TH>
<P>ClinicalTrials.gov</P>
</TH>
</TR>
<TR>
<TD>
<P>
<I>Advanced Search</I>
<BR/>
<B>Search terms: </B>((diabetic OR diabetes) AND (ketoacidosis OR ketoacidoses OR acidosis OR acidoses OR ketosis OR ketoses OR coma)) AND (lispro OR aspart OR glulisine OR acting insulin OR apidra OR humulin OR novolin OR novolog OR novorapid OR analogue OR analogues)</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-01-20 10:42:36 +0100" MODIFIED_BY="Gudrun Paletta" NO="2">
<TITLE MODIFIED="2014-09-10 16:10:39 +0200" MODIFIED_BY="Gudrun Paletta">Description of interventions</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-20 10:42:36 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="5" ROWS="8">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s)<BR/>
</P>
</TH>
<TH VALIGN="TOP">
<P>Adequate<SUP>a</SUP> intervention</P>
<P>(Yes/No)</P>
</TH>
<TH VALIGN="TOP">
<P>Comparator(s)<BR/>
</P>
</TH>
<TH VALIGN="TOP">
<P>Adequate<SUP>a</SUP> comparator</P>
<P>(Yes/No)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Subcutaneous insulin lispro every hour: initial injection of 0.3 units/kg followed by 0.1 unit/kg/h until blood glucose levels reached 250 mg/dL; the insulin dose was then reduced to 0.05 units/kg/h, and the intravenous fluids were changed to dextrose 5% in 0.45% normal saline to keep blood glucose at a level of about 200 mg/dL until resolution of DKA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intravenous regular insulin: initial bolus of 0.1 units/kg, followed by a continuous infusion of 0.1 units/kg/h until blood glucose levels decreased to approx. 250 mg/dL; at this time, intravenous fluids were changed to dextrose-containing solutions, and the insulin infusion rate was decreased to 0.05 units/kg/h until resolution of DKA</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I1: initial injection of 0.3 units/kg, followed by 0.1 units/kg/h until blood glucose reached 250 mg/dL; the insulin dose was then reduced to 0.05 units/kg/h, and the intravenous fluids were changed to dextrose 5%, 0.45 saline to maintain blood glucose at 200 mg/dL until resolution of DKA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Intravenous regular insulin: initial bolus of 0.1 units/kg, followed by a continuous infusion of regular insulin calculated to deliver 0.1 units/kg/h until blood glucose levels were 250 mg/dL; the insulin dose was then reduced to 0.05 units/kg/h, and the intravenous fluids were changed to dextrose 5%, 0.45 saline to maintain blood glucose at 200 mg/dL until resolution of DKA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Yes</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I2: initial dose of 0.3 units/kg followed by 0.2 units/kg 1 h later and every 2 h until blood glucose reached 250 mg/dL; the insulin dose was then reduced to 0.1 units/kg every 2 h, and the intravenous fluids were changed to dextrose 5%, 0.45 saline to keep blood glucose at 200 mg/dL until resolution of DKA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.15 units/kg of a insulin lispro was administered subcutaneously every 2 h; when capillary blood glucose levels neared 249 mg/dL, 0.15 units/kg were administered every 4 h for the next 24 h</P>
<P/>
<P>After approx. 12 h of intensive insulin administration, intermediate human insulin was initiated at a dosage of 0.4 unit/kg every 12 h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Regular insulin was infused with a syringe pump at a rate of 0.1 unit/kg/h from an independent intravenous line through a second catheter inserted into a peripheral vein. This infusion was continued until capillary blood glucose levels decreased to &#8804; 249 mg/dL; thereafter, 0.15 units/kg regular insulin were given subcutaneously 30 min before stopping the intravenous line and every 4 h for the next 24 h</P>
<P/>
<P>After approx. 12 h of intensive insulin administration, intermediate human insulin was initiated at a dosage of 0.4 unit/kg every 12 h</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Following a bolus injection of 0.15 units/kg i.v. regular insulin, group L received half of this dose as hourly s.c. insulin lispro. Insulin dose was titrated according to serum glucose and pH levels; if serum glucose did not fall by 50-70 mg/dL in the first hour, insulin dose was planned to be doubled hourly until glucose fell by 50-70 mg/dL</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Following a bolus injection of 0.15 units/kg i.v. regular insulin, group R was treated conventionally with standard i.v. regular insulin infusion. Insulin dose was titrated according to serum glucose and pH levels; if serum glucose did not fall by 50-70 mg/dL in the first hour, insulin dose was planned to be doubled hourly until glucose fell by 50-70 mg/dL</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Initial bolus of 0.3 units/kg followed by 0.2 units/kg 1 h later and then 0.2 units/kg every 2 h until blood glucose reached 250 mg/dL; the insulin dose was then reduced to 0.1 units/kg/h to keep blood glucose at approx. 200 mg/dL<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Initial bolus of regular insulin 0.1 unit/kg i.v. followed by continuous infusion of regular insulin calculated to deliver 0.1 unit/kg/h until blood glucose levels decreased to approx. 250 mg/dL; the insulin infusion rate was then decreased to 0.05 units/kg/h until resolution of DKA, and intravenous fluids were changed to dextrose-containing solutions (5% dextrose) to keep blood glucose level at approx. 200 mg/dL<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>
<SUP>a</SUP>The term 'adequate' refers to sufficient use of the intervention/comparator with regard to dose, dose escalation, dosing scheme, provision for contraindications, and other features necessary to establish a fair contrast between intervention and comparator.</P>
<P>DKA: diabetic ketoacidosis; I: intervention</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-01-20 10:42:48 +0100" MODIFIED_BY="Gudrun Paletta" NO="3">
<TITLE MODIFIED="2014-09-10 16:10:44 +0200" MODIFIED_BY="Gudrun Paletta">Baseline characteristics (I)</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-20 10:42:48 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="9" ROWS="13">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Duration of intervention<BR/>(duration of follow-up)<BR/>[days, months, years ...]<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Description of participants</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Trial period<BR/>[year to year]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Country</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Setting</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Ethnic groups<BR/>[%]</P>
</TH>
<TH VALIGN="TOP">
<P>Duration of diabetes [mean/range years (SD), or as reported]</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resolution of DKA: mean 10 h</P>
<P>(mean hospital stay: 4 d)</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Adults with "uncomplicated" DKA (not stated if type 1 or 2 diabetes)</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Regional medical centre</P>
<P>DKA established in the ED</P>
<P>Regular medicine ward, intermediate care unit (step-down unit)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>African American: 75</P>
</TD>
<TD VALIGN="TOP">
<P>6.7 (5)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resolution of DKA: mean 11 h</P>
<P>(mean hospital stay: 4 d)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Regional medical centre</P>
<P>DKA established in the ED</P>
<P>ICU</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>African American: 80</P>
</TD>
<TD VALIGN="TOP">
<P>6.9 (4)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I1: s.c. insulin aspart, every hour</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resolution of DKA: mean 10 h</P>
<P>(mean hospital stay: 3.4 d)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Adults with "uncomplicated" DKA (not stated if type 1 or 2 diabetes)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Regional medical centre</P>
<P>DKA established in the ED</P>
<P>General medical ward or step-down unit</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I2: s.c. insulin aspart, every 2 h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resolution of DKA: mean 10.7 h</P>
<P>(mean hospital stay: 3.9 d)<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resolution of DKA: mean 11 h</P>
<P>(mean hospital stay: 4.5 d)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Regional medical centre<BR/>DKA established in the ED<BR/>
</P>
<P>ICU</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resolution of metabolic acidosis/ketosis: "in the next 6 h interval" (later than after i.v. regular insulin)</P>
<P>Resolution of DKA: 12 h after capillary glucose &lt; 250 mg/dL</P>
<P>(mean hospital stay 2-3 d)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Children and adolescents with DKA</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>2001 to 2003</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Brazil</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>University children's hospital, 57 DKA episodes treated in ED, 3 DKA episodes treated in ICU</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resolution of metabolic acidosis/ketosis: 6 h after capillary glucose &#8804; 250 mg/dL</P>
<P>Resolution of DKA: 12 h after capillary glucose &lt; 250 mg/dL</P>
<P>(mean hospital stay 2-3 d)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Resolution of DKA: no data<BR/>(hospital stay: no data)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Adults with mild or moderate DKA (not stated if type 1 or 2 diabetes)</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Turkey</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>3.9 (4.5)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD VALIGN="TOP">
<P>4.5 (4.3)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resolution of DKA: mean 12 h</P>
<P>(mean hospital stay 6 d)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Adults with mild to moderate DKA (&gt; 50% of participants had type 2 diabetes)</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>2009 to 2010</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>India</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Teaching hospital, ED</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>6.4 (5)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resolution of DKA: mean 11 h</P>
<P>(mean hospital stay 6.6 d)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Teaching hospital, ICU</P>
</TD>
<TD VALIGN="TOP">
<P>6.8 (4)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>- denotes not reported</P>
<P>C: comparator; d: days; DKA: diabetic ketoacidosis; ED: emergency department; h: hours; I: intervention; ICU: intensive care unit; i.v.: intravenous; s.c.: subcutaneous; SD: standard deviation</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-01-20 10:39:28 +0100" MODIFIED_BY="Gudrun Paletta" NO="4">
<TITLE MODIFIED="2014-09-10 16:10:49 +0200" MODIFIED_BY="Gudrun Paletta">Baseline characteristics (II)</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-20 10:39:28 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="9" ROWS="13">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Sex<BR/>[female %]<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Glucose levels at admission<BR/>(mean mg/dL (SD))</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Age<BR/>(mean years (SD))</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>HbA1c<BR/>(mean % (SD))</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>BMI<BR/>(mean kg/m² (SD))</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Comedications / Cointerventions</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Comorbidities</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>674 (154)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>37 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26 (7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>611 (264)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 (14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 (9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I1: s.c. insulin aspart, every hour</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>787 (378)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36 (8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11.5 (1.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 (6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27% had an associated comorbid condition (leg abscess, pneumonia, urinary tract infection, pancreatitis)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I2: s.c. insulin aspart, every 2 h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>758 (373)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11.4 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29 (7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27% had an associated medical illness (cellulitis, urinary tract infection, olanzapine overdose, failure to take oral antidiabetic agent)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>717 (239)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 (13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11.7 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 (7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27% had an associated medical illness (pneumonia, cellulitis, urinary tract infection, and tooth abscess)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>434 (142)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>76</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>434 (146)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>512 (138)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 (20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13.9 (2.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Retinopathy/neuropathy/nephropathy/cardiovascular disease/cerebrovascular disease: 10%/10%/0%/10%/10%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>556 (43)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>49 (18)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11.6 (1.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Retinopathy/neuropathy/nephropathy/cardiovascular disease/cerebrovascular disease: 20%/20%/0%/30%/0%</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>650 (113)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>34 (13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25 (3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>679 (125)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>- denotes not reported</P>
<P>BMI: body mass index; C: comparator; HbA1c: glycosylated haemoglobin A1c; I: intervention; i.v.: intravenous; s.c.: subcutaneous; SD: standard deviation</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-01-20 10:39:28 +0100" MODIFIED_BY="Gudrun Paletta" NO="5">
<TITLE MODIFIED="2015-07-08 11:39:00 +0200" MODIFIED_BY="[Empty name]">Matrix of study endpoints (publications and trial documents)</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-20 10:39:28 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="5" ROWS="17">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Endpoints quoted in trial document(s)<BR/>(ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper)<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Study results posted in trial register, publications specified in trial register</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Endpoints quoted in publication(s)<SUP>b,c</SUP>
<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Endpoints quoted in abstract of publication(s)<SUP>b,c</SUP>
</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P>N/T</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s):</B> response to medical therapy: the time required for resolution of hyperglycaemia and ketoacidosis, and the rate of hypoglycaemia during insulin infusion</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s):</B> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> levels of blood glucose, electrolytes, phosphorus, venous pH, beta-hydroxybutyrate, free fatty acids, insulin; medical care data (site of admission and treatment in the hospital, amount of fluid and insulin administration, length of hospitalisation); deaths</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> duration of treatment until correction of hyperglycaemia and resolution of ketoacidosis, deaths, length of hospital stay, amount of insulin until resolution of diabetic ketoacidosis, rate of hypoglycaemia, hospitalisation charges<BR/>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P>N/T</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s):</B> time to resolve ketoacidosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s):</B> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s): </B>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> levels of glucose, electrolytes, phosphorus, venous pH, beta-hydroxybutyrate, free fatty acids, insulin; response to medical<BR/>therapy (time and amount of insulin required for resolution of hyperglycaemia and ketoacidosis and the number of hypoglycaemic events during therapy)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> duration of treatment until resolution of hyperglycaemia and ketoacidosis, total length of hospitalisation, amount of insulin administration until resolution of hyperglycaemia and ketoacidosis, number of hypoglycaemic events</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P>N/T</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s):</B> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s): -</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s): -</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> blood glucose, blood gas, beta-hydroxybutyrate, electrolytes, phosphate, magnesium, urea nitrogen, creatinine, urine ketones; resolution of metabolic acidosis and ketosis, DKA recovery; (near) deaths, cerebral oedema; hypoglycaemic episodes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> blood glucose, blood gas, beta-hydroxybutyrate, electrolytes, metabolic acidosis and ketosis, DKA recovery</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P>N/T</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s):</B> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s):</B> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> serum glucose, pH, beta-hydroxybutyrate, electrolytes, urine ketone levels and urinary output, lipids; resolution of ketoacidosis, time elapsed until normalisation of the monitored parameters, total amount of insulin delivered until resolution of DKA; mortality, hypoglycaemic events</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> time needed for normalisation of serum glucose, beta-hydroxybutyrate, blood pH and urine ketone levels; mortality, serious side effects<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P>N/T</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s):</B> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primary outcome measure(s):</B> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Secondary outcome measure(s):</B> -</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> blood glucose levels, resolution of DKA, response to therapy was assessed by time and amount of insulin required for resolution of hyperglycaemia and ketoacidosis, number of hypoglycaemic events; duration of hospital stay; deaths<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Other outcome measure(s):</B> response to therapy (duration of treatment and amount of insulin administered until resolution of hyperglycaemia and ketoacidosis, total length of hospital stay, and number of hypoglycaemic events); mortality<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>- denotes not reported</P>
<P>
<SUP>a</SUP>Trial document(s) refers to all available information from published design papers and sources other than regular publications (e.g. FDA/EMA documents, manufacturers' websites, trial registers)<BR/>
<SUP>b</SUP>Publication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion documents, or multiple reports of a primary study)<BR/>
<SUP>c</SUP>Other outcome measures refer to all outcomes not specified as primary or secondary outcome measures<BR/>
</P>
<P>DKA: diabetic ketoacidosis; EMA: European Medicines Agency; FDA: US Food and Drug Administration; N/T: no trial document available</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-01-20 10:39:28 +0100" MODIFIED_BY="Gudrun Paletta" NO="6">
<TITLE MODIFIED="2014-09-10 16:10:58 +0200" MODIFIED_BY="Gudrun Paletta">Examination of outcome reporting bias according to ORBIT classification</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-20 10:39:28 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="6" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Outcome</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>High risk of bias<BR/>(category A)<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>High risk of bias<BR/>(category D)<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>High risk of bias<BR/>(category E)<SUP>c</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>High risk of bias<BR/>(category G)<SUP>d</SUP>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time to resolution of DKA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time to resolution of DKA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<SUP>a</SUP>Clear that outcome was measured and analysed; trial report states that outcome was analysed but reports only that result was not significant.<BR/>(Classification 'A', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>)<BR/>
<SUP>b</SUP>Clear that outcome was measured and analysed; trial report states that outcome was analysed, but no results reported.<BR/>(Classification 'D', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>)<BR/>
<SUP>c</SUP>Clear that outcome was measured but not necessarily analysed; judgement says likely to have been analysed but not reported because of non-significant results.<BR/>(Classification 'E', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>)<BR/>
<SUP>d</SUP>Unclear whether the outcome was measured; not mentioned, but clinical judgement says likely to have been measured and analysed but not reported on the basis of non-significant results.<BR/>(Classification 'G', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>)</P>
<P>DKA: diabetic ketoacidosis; N/A: not applicable; ORBIT: Outcome Reporting Bias In Trials<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2016-01-18 15:55:22 +0100" MODIFIED_BY="Gudrun Paletta" NO="7">
<TITLE MODIFIED="2014-09-10 16:11:02 +0200" MODIFIED_BY="Gudrun Paletta">Definition of endpoint measurement (I)</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 15:55:22 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="7" ROWS="7">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Resolution of diabetic ketoacidosis</P>
</TH>
<TH VALIGN="TOP">
<P>All-cause mortality</P>
</TH>
<TH VALIGN="TOP">
<P>Morbidity</P>
</TH>
<TH VALIGN="TOP">
<P>Patient satisfaction</P>
</TH>
<TH VALIGN="TOP">
<P>HbA1c</P>
</TH>
<TH VALIGN="TOP">
<P>Socioeconomic effects</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Serum bicarbonate level &#8805; 18 mEq/L and venous pH &gt; 7.30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/D</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hospital stay in days and cost as data on hospital charges</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Serum bicarbonate level &#8805; 18 mmol/L and venous pH &gt; 7.30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/D</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Length of hospital stay in days</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mentally alert and able to eat, serum bicarbonate &gt; 15 mmol/L, venous pH &gt; 7.30, anion gap &lt; 16 mmol/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/D</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cerebral oedema</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Serum glucose &lt; 200 mg/dL , serum bicarbonate level &gt; 18 mmol/L, venous pH &gt; 7.30, capillary hydroxybutyrate level &lt; 0.6 mmol/L, and negative urine ketone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/D</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Serum bicarbonate level &gt; 18 mmol/L and arterial pH &gt; 7.30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/D</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Venous thrombosis, adult respiratory distress syndrome, hyperchloraemic acidosis<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>HbA1c: glycosylated haemoglobin A1c; N/D: not defined; N/I: not investigated</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2016-01-18 15:27:04 +0100" MODIFIED_BY="Gudrun Paletta" NO="8">
<TITLE MODIFIED="2014-09-14 22:11:15 +0200" MODIFIED_BY="[Empty name]">Definition of endpoint measurement (II)</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 15:27:04 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="5" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>All hypoglycaemic events</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Severe hypoglycaemia</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Nocturnal hypoglycaemia</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Severe/serious<BR/>adverse events</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8804; 60 mg/dL</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8804; 60 mg/dL</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 60 mg/dL, described as "mild"</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/D</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/D</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 60 mg/dL, described as "mild"</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/I</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>N/D: not defined; N/I: not investigated</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2016-01-18 15:28:24 +0100" MODIFIED_BY="Gudrun Paletta" NO="9">
<TITLE MODIFIED="2014-09-10 16:11:25 +0200" MODIFIED_BY="Gudrun Paletta">Adverse events (I)</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 15:28:24 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="9" ROWS="13">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants included in analysis<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Deaths<BR/>[N]<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Deaths<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with at least one adverse event<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with at least one adverse event<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with at least one severe/serious adverse event<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with at least one severe/serious adverse event<BR/>[%]</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I1: s.c. insulin aspart, every hour</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I2: s.c. insulin aspart, every 2 h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>- denotes not reported</P>
<P>C: comparator; I: intervention; i.v.: intravenous; s.c.: subcutaneous</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2016-01-18 15:53:41 +0100" MODIFIED_BY="Gudrun Paletta" NO="10">
<TITLE MODIFIED="2014-09-10 16:11:29 +0200" MODIFIED_BY="Gudrun Paletta">Adverse events (II)</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 15:53:41 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="5" ROWS="13">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants included in analysis<BR/>[N]</P>
</TH>
<TH VALIGN="TOP">
<P>Participants discontinuing trial due to an adverse event<BR/>[N]</P>
</TH>
<TH VALIGN="TOP">
<P>Participants discontinuing trial due to an adverse event<BR/>[%]</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I1: s.c. insulin aspart, every hour</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I2: s.c. insulin aspart, every 2 h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>- denotes not reported</P>
<P>C: comparator; I: intervention; i.v.: intravenous; s.c.: subcutaneous</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-11" MODIFIED="2016-01-18 15:30:32 +0100" MODIFIED_BY="Gudrun Paletta" NO="11">
<TITLE MODIFIED="2015-10-15 11:49:48 +0200" MODIFIED_BY="Bernd Richter">Adverse events (III)</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 15:30:32 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="9" ROWS="13">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants included in analysis<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with hypoglycaemic episodes<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with hypoglycaemic episodes<BR/>[%]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with nocturnal hypoglycaemic episodes<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with nocturnal hypoglycaemic episodes<BR/>[% participants]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with severe/serious hypoglycaemic episodes<BR/>[N]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Participants with severe/serious hypoglycaemic episodes<BR/>[%]</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I1: s.c. insulin aspart, every hour</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I2: s.c. insulin aspart, every 2 h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>I: s.c. insulin lispro</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>C: i.v. regular insulin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>- denotes not reported</P>
<P>C: comparator; I: intervention; i.v.: intravenous; s.c.: subcutaneous</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-12" MODIFIED="2016-01-20 10:44:15 +0100" MODIFIED_BY="Gudrun Paletta" NO="12">
<TITLE MODIFIED="2015-10-22 10:28:56 +0200" MODIFIED_BY="Bernd Richter">Checklist to aid consistency and reproducibility of GRADE assessments</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-20 10:44:15 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="9" ROWS="31">
<TR>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>'Summary of findings' tables outcome measures (for both insulin lispro and insulin aspart)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>All-cause mortality</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hypoglycaemic episodes</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Morbidity</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Adverse events other than hypoglycaemic episodes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Time to resolution of diabetic ketoacidosis</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Patient satisfaction</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Socioeconomic effects (length of hospital stay)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="9" VALIGN="TOP">
<P>Trial limitations<BR/>(risk of bias)<SUP>a</SUP>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was random sequence generation used (i.e. no potential for selection bias)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes/unclear</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="29" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="29" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="29" VALIGN="TOP">
<P>N/I</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes/unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was allocation concealment used (i.e. no potential for selection bias)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was there blinding of participants and personnel (i.e. no potential for performance bias)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was there blinding of outcome assessment (i.e. no potential for detection bias)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was an objective outcome used?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Were more than 80% of participants enrolled in trials included in the analysis (i.e. no potential reporting bias)?<SUP>e</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Were data reported consistently for the outcome of interest (i.e. no potential selective reporting)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No other biases reported (i.e. no potential for other bias)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Did the trials end as scheduled (i.e. not stopped early)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="5" VALIGN="TOP">
<P>Inconsistency<SUP>b</SUP>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Point estimates did not vary widely?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes<SUP>f</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>To what extent did confidence intervals overlap (substantial: all confidence intervals overlap at least 1 of the included studies' point estimate;<BR/>some: confidence intervals overlap, but not all overlap at least 1 point estimate; no: at least 1 outlier: where the confidence interval of some of the studies does not overlap with those of most included studies)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Substantial<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Substantial<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Substantial<SUP>f</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was the direction of effect consistent?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes<SUP>f</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>What was the magnitude of statistical heterogeneity (as measured by I²): low (I² &lt; 40%), moderate (I² 40% - 60%), high (I² &gt; 60%)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High (&#8595;)<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low<SUP>f</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was the test for heterogeneity statistically significant (P &lt; 0.1)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not statistically significant<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not statistically significant<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not statistically significant<SUP>f</SUP>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="5" VALIGN="TOP">
<P>Indirectness<SUP>a</SUP>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Were the populations in the included studies applicable to the decision context?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Highly applicable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Highly applicable</P>
<P/>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Highly applicable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Highly applicable</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Were the interventions in the included studies applicable to the decision context?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Highly applicable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Highly applicable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Highly applicable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Highly applicable</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was the included outcome not a surrogate outcome?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was the outcome time frame sufficient?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sufficient</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sufficient</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sufficient</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sufficient</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Were the conclusions based on direct comparisons?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Imprecision<SUP>c</SUP>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was the confidence interval for the pooled estimate not consistent with benefit and harm?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)<SUP>f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)<SUP>f</SUP>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)<SUP>f</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>What is the magnitude of the median sample size (high: 300 participants, intermediate: 100-300 participants, low: &lt; 100 participants)?<SUP>e</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intermediate<SUP>g</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intermediate<SUP>g</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low (&#8595;)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low (&#8595;)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>What was the magnitude of the number of included studies (large: &gt; 10 studies, moderate: 5-10 studies, small: &lt; 5 studies)?<SUP>e</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Small (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Small (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Small (&#8595;)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Small (&#8595;)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was the outcome a common event (e.g. occurs more than 1/100)?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>Publication bias<SUP>d</SUP>
</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was a comprehensive search conducted?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Was grey literature searched?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Were no restrictions applied to study selection on the basis of language?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>There was no industry influence on studies included in the review?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No (&#8595;)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>There was no evidence of funnel plot asymmetry?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>There was no discrepancy in findings between published and unpublished trials?</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<SUP>a</SUP>Questions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual trials<BR/>
<SUP>b</SUP>Questions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on I²<BR/>
</P>
<P>
<SUP>c</SUP>When judging the width of the confidence interval, it is recommended to use a clinical decision threshold to assess whether the imprecision is clinically meaningful<BR/>
<SUP>d</SUP>Questions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between published and unpublished trials<BR/>
<SUP>e</SUP>Depends on the context of the systematic review area</P>
<P>
<SUP>f</SUP>N/A for insulin aspart</P>
<P>
<SUP>g</SUP>Low for insulin aspart</P>
<P>(&#8595;): key item for possible downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of findings' table(s)<BR/>GRADE: Grading of Recommendations Assessment, Development and Evaluation; N/A: not applicable; N/I: not investigated</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-13" MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="13">
<TITLE MODIFIED="2014-09-10 16:11:44 +0200" MODIFIED_BY="Gudrun Paletta">Survey of authors providing information on included trials</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-20 10:39:29 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="5" ROWS="9">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Date trial author contacted<BR/>
<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Date trial author replied<BR/>
<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial author asked for additional information<BR/>[short summary]<BR/>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial author provided data<BR/>[short summary]<BR/>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Umpierrez 2004a</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No reply</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Umpierrez 2004b</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No reply</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Della Manna 2005</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No reply</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Ersöz 2006</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No reply</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Karoli 2011</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No reply</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>El Ebrashy 2010</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No reply</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Baldwin 2009</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 April 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No reply</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5">
<P>N/A: not applicable</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2012-04-27 13:28:03 +0200" MODIFIED_BY="Bernd Richter">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="471">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 completed studies (5 publications) included in qualitative synthesis&lt;/p&gt;" WIDTH="548">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 potentially relevant trials (7 publications)&lt;/p&gt;" WIDTH="214">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional studies identified through handsearching of reference lists of included trials, systematic reviews/meta-analyses, and HTA reports&lt;/p&gt;" WIDTH="587">
<FLOWCHARTBOX TEXT="&lt;p&gt;23 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="335">
<FLOWCHARTBOX TEXT="&lt;p&gt;492 records screened&lt;/p&gt;" WIDTH="183">
<FLOWCHARTBOX TEXT="&lt;p&gt;492 records after duplicates removed&lt;/p&gt;" WIDTH="311">
<FLOWCHARTBOX TEXT="&lt;p&gt;645 records identified through database searching&lt;/p&gt;&lt;p&gt;Cochrane Library: n = 58&lt;br&gt;MEDLINE: n = 152&lt;br&gt;PubMed: n = 20&lt;br&gt;EMBASE: n = 307&lt;br&gt;LILACS: n = 7&lt;br&gt;CINAHL: n = 32&lt;br&gt;ICTRP: n = 4&lt;br&gt;ClinicalTrials.gov: n = 65&lt;/p&gt;" WIDTH="358"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;11 additional records identified through non-database sources (contacts with experts, manufacturers, handsearching of literature)&lt;/p&gt;" WIDTH="533"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;469 records excluded&lt;/p&gt;" WIDTH="174"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;16 full-text articles excluded&lt;/p&gt;&lt;p&gt;1. Aim was not treating DKA: n = 4&lt;br&gt;2. Not an RCT: n = 4&lt;br&gt;3. Intervention not relevant: n = 8&lt;/p&gt;" WIDTH="287"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;2 studies (2 publications) awaiting classification&lt;/p&gt;" WIDTH="209"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>